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Résumé 
Afin d’effectuer des études fonctionnelles sur le génome de la souris, notre laboratoire a 
généré une bibliothèque de clones de cellules souches embryonnaires (ESC) présentant des 
suppressions chromosomiques chevauchantes aléatoires  – la bibliothèque DELES. Cette 
bibliothèque contient des délétions couvrant environ 25% du génome murin. 
 
Dans le laboratoire, nous comptons identifier de nouveaux déterminants du destin des cellules 
hématopoïétiques en utilisant cet outil. Un crible primaire utilisant la benzidine pour 
démontrer la présence d'hémoglobine dans des corps embryoïdes (EBS) a permis d’identifier 
plusieurs clones délétés présentant un phénotype hématopoïétique anormal. Comme cet essai 
ne vérifie que la présence d'hémoglobine, le but de mon projet est d'établir un essai in vitro de 
différenciation des ESC permettant de mesurer le potentiel hématopoïétique de clones 
DELES. Mon hypothèse est que l’essai de différenciation hématopoïétique publié par le Dr 
Keller peut être importé dans notre laboratoire et utilisé pour étudier l'engagement 
hématopoïétique des clones DELES. À l’aide d’essais de RT-QPCR et  de FACS, j’ai pu 
contrôler la cinétique de différenciation hématopoïétique en suivant l’expression des gènes 
hématopoïétiques et des marqueurs de surface comme CD41, c-kit, RUNX1, GATA2, CD45, 
β-globine 1 et TER-119. Cet essai sera utilisé pour valider le potentiel hématopoïétique des 
clones DELES candidats identifiés dans le crible principal. 
 
Mon projet secondaire vise à utiliser la même stratégie rétro-virale a base de Cre-loxP utilisée 
pour générer la bibliothèque DELES pour générer une bibliothèque de cellules KBM-7 
contenant des suppressions chromosomiques chevauchantes. Mon but ici est de tester si la 
lignée cellulaire leuémique humaine presque haploïde KBM-7 peut être exploitée en utilisant 
l'approche DELES pour créer cette bibliothèque. La bibliothèque de clones KBM-7 servira à 
définir les activités moléculaires de drogues anti-leucémiques potentielless que nous avons 
identifiées dans le laboratoire parce qu’elles inhibent la croissance cellulaire dans plusieurs 
échantillons de leucémie myéloïde aiguë dérivés de patients. Elle me permettra également 
d'identifier les voies de signalisation moléculaires qui, lorsque génétiquement perturbées, 
peuvent conférer une résistance à ces drogues. 
 
Mots-clés: cellules souches embryonnaires, différenciation hématopoïétique, cellules KBM-7, 
suppressions chromosomiques. 
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Abstract 
To carry out functional studies on the mouse genome, our laboratory has generated a library of 
Embryonic Stem Cell (ESC) clones harboring random nested chromosomal deletions – 
DELES library. This library contains deletions covering ~ 25% of the mouse genome. 
 
In the lab, we are interested in identifying novel hematopoietic cell fate determinants using 
this resource. A primary screen using benzidine to demonstrate the presence of hemoglobin in 
embryoid bodies (EBs) was able to identify several DELES clones exhibiting abnormal 
hematopoietic phenotype. Since this assay only tested for the presence of hemoglobin, the goal 
of my project is to establish a robust in vitro ESC differentiation assay to monitor the 
hematopoietic potential of DELES clones. My hypothesis is that the hematopoietic 
differentiation assay published by Dr. Keller can be used to observe hematopoietic 
commitment of the DELES clones. Using QRT-PCR and FACS assays I was able to monitor 
the kinetics of hematopoietic differentiation by observing the expression of hematopoietic genes 
and surface markers including CD41, C-KIT, RUNX1, GATA2, CD45, β-GLOBIN 1 and TER-
119. This assay will be used to validate the hematopoietic potential of the candidate DELES 
clones identified in the primary screen.   
 
My secondary project aims to use the same retro-viral Cre-loxP strategy used for the DELES 
library, in order to generate a library of KBM-7 leukemic cells harboring nested chromosomal 
deletions. My goal here is to test if the human near haploid KBM-7 cell line can be exploited 
using the DELES approach to create this library. The library of KBM-7 clones will be used to 
delineate the molecular activities of potential anti-leukemic drugs that we have identified in 
the lab to inhibit cell growth in several patient-derived acute-myeloid leukemia specimens. It 
will also allow me to identify molecular signaling pathways that, when genetically disrupted, 
can confer resistance to these drugs.  
 
Keywords: Embryonic stem cells, hematopoietic differentiation, KBM-7 cells, chromosomal 
deletions. 
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1. Introduction 
Embryonic stem cells (ESCs) have two main characteristics – self renewal and pluripotency. 
Self-renewal is a mechanism by which a cell can generate a daughter cell identical to itself. 
ESCs undergo symmetric cell division to generate two identical daughter cells. Pluripotency 
refers to the ability of a cell to differentiate into the three primary germ layers – ectoderm, 
mesoderm and endoderm. [1] 
                                                                                                      
 
Figure 1: Illustration of the origin and differentiation of the three germ layers.              
(Permission obtained from Terese Winslow 
http://stemcells.nih.gov/StaticResources/info/scireport/images/figure11.jpg) 
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Mouse Embryonic Stem Cells (mESCs) are pluripotent cells isolated from the inner cell mass 
(ICM) of day 3.5 preimplantation blastocyst. The ICM isolated from the blastocyst has the 
potential to give rise to all the three germ layers. It is however unable to contribute to the 
trophectoderm and primitive endoderm lineages. [2] When maintained under appropriate 
conditions these ICM cells give rise to ESC cell lines that have normal karyotype and high 
telomerase activity. Each cell line is defined by colonies derived from a single blastocyst; 
therefore all ESC cell lines are genetically unique. Most ES cell lines are 40XY, this is 
because in XX ES cell lines there is a global reduction of DNA methylation due to the 
presence of two active X chromosomes (one X chromosome eventually becomes inactive). 
This hypomethylation affects the long term maintenance of these cell lines in culture. [3, 4] 
One of the most debated questions in the embryonic stem cell field is whether ES cells are 
artifacts of tissue culture or/and whether they relate to a specific cell type in-vivo?  ESCs 
exhibit some characteristics that are not shown in vivo by cells within an embryo; an example 
of one such property is that, no cell in the embryo demonstrates long-term self-renewal and 
pluripotency. When embryonic cells are brought to culture and exposed to specific signals (to 
which they wouldn’t have been exposed to in vivo), they adapt and procure novel functions 
that enable them to maintain their pluripotency and self-renewal abilities indefinitely. Studies 
have suggested that within the embryo there is a transient population of cells that are 
pluripotent and possess self-renewal capabilities, however, this population is present in vivo 
for only a limited period of time. These cells become more restricted in their potency as 
development progresses. Therefore, one can say that ES cells are a tissue culture artifact. [5] 
 
ES cell lines can be derived from the ICM, primitive ectoderm and possibly from early germ 
cells. (Figure 3) mESCs are not equivalent to ICM cells because the ICM cells are capable of 
differentiating into the trophoblast whereas mESCs cannot. [5] mESCs are not entirely 
equivalent to germ cells as early germ cells do not self-renew for an extended period of time. 
It is shown that primordial germ cells (PGCs) do not contribute to chimeras when injected into 
blastocysts. [5] Studies have shown a founder population of cells that emerges from the 
primitive ectoderm before gastrulation that passes through the primitive streak to give rise to 
many structures of the extraembryonic mesoderm and the germ cells. The inductive signaling 
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involved in this process might be reproducible in vitro. ESCs might be related to this founder 
population. [5] 
 
 
Figure 2: Illustration of the origin of stem cells. (Fiona M. Watt, Ryan R. Driskell. Phil. 
Trans. R. Soc B (2009).365 155-163, Permission obtained from the journal). 
 
Embryonic stem cells are an interesting model in research for several reasons. Due to their 
self-renewal ability, they can be cultured in vitro for an extended period of time - serving as a 
constant supply of starting material. [6] mESCs can be used to generate mouse chimeras when 
re-introduced into a blastocyst. The pluripotency of ESCs enable them to differentiate into the 
three germ layers, making them an excellent model to study most developmental processes. 
Finally their genome is well characterized and easily modifiable using different mutagenesis 
strategies. [6, 7]  
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1.1 Genomic approaches used to conduct functional studies on    
ESCs. 
Over the years, several genome editing strategies have been developed to conduct functional 
studies on the mouse genome. In this section, I will briefly explain a few strategies that have 
gained popularity in the past decade. 
 1.1.1 Gene targeting  
Gene targeting is an approach that relies on homologous recombination to modify an 
endogenous target gene. [8] This strategy requires the creation of a vector that contains  a part 
of the gene to be modified, a reporter gene and a selection marker gene flanked by two 
homology arms. [8] To prevent unwanted effects caused by the presence of selection marker 
genes, Cre-loxP or Flp-frt technologies can be used to excise these genes. 
The type and exact location of the mutation is known to us when we use this strategy. This 
offers us an advantage when we wish to recover these mutations. One of the drawbacks 
associated with this approach is that it requires germ-line competent ES cells. When 
recombinant ES cells are injected into the blastocoel cavity of 3.5 day old embryos to generate 
chimeric mice, it is important they colonize the germ cells of the animal to propagate the 
targeted mutation to subsequent generations. When using any genetic mutation strategy we 
must keep in mind that genetic redundancy can result in compensatory effects thereby possibly 
impeding the functional analysis of the mutation. [9] Sometimes the targeted gene of interest 
is involved in embryonic viability in the early stages of development and has several different 
functions at the later stages of development. [9] Abrogation of such genes results in embryonic 
lethality preventing the study of the genes’ function in later developmental processes. The 
design of conditional recombinase systems, allowing the abrogation of gene expression in a 
spatio-temporal controlled manner has helped overcome this limitation. [10] 
 
The International Knockout Mouse Consortium (IKMC), Knockout Mouse Project Repository 
(KOMP), European Conditional Mouse Mutagenesis Program (EUCOMM) and North 
American Conditional Mouse Mutagenesis Project (NorCOMM) are some of the international 
efforts in place that employ gene targeting to study the functional mammalian genome. 
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1.1.2 siRNA and shRNA screens 
 Though RNA interference technology is not a genome editing strategy, it allows us to study 
loss of function effects of specific genes in the mammalian genome by degrading the specific 
gene mRNAs. [11] Two approaches that have gained interest for achieving gene silencing are 
ds-small interfering RNA (siRNA) and vector based short hairpin RNA (shRNAs). While both 
approaches result in gene silencing, they differ in their mechanisms of action. In siRNA 
screens, dsRNA is synthesized complementary to the gene of interest and is introduced into 
the cytosol of the cells through transfection. Upon introduction to the cell, a ds-RNA specific 
enzyme Dicer forms a complex with long dsRNAs and cleaves them into shorter fragments of 
20-25bp. The cleaved fragments are then incorporated into the RISC complex which is 
comprised of Arogonaute 2 (Ago-2), Dicer and TAR-RNA binding protein (TRBP). The RNA 
duplex is dissociated, the strand with the lowest duplex stability remains in complex with the 
RISC while the other strand is removed.[12] 
shRNAs can be delivered to the cells by infection with virally produced vectors or through 
transfection with plasmid vectors encoding them. shRNAs consists of two complementary 19-
22 bp RNA sequences linked by a loop of 4-11 nucleotides. shRNAs are transcribed by RNA 
polymerase II or III based on the promoter driving their expression. Drosha and its dsRNA-
binding partner DGCR8 processes these initial precursors to pre-shRNAs which is then 
exported to the cytoplasm by Exportin-5. Dicer and TRBP/PACT cleaves these pre-shRNAs, 
removing the hairpin and creating a 20-25 nucleotide ds-siRNA which is then loaded onto the 
RISC complex.[12] 
Once the fragments are loaded onto the RISC, the process by which siRNA and shRNA 
recognizes and degrades the target mRNA is the same. As part of the RISC, siRNA binds to 
the target mRNA mediated by complementary base pairing. This leads to the cleavage of the 
target RNA phosphate backbone around the center of the duplex by the action of Ago-2. 
RNAi-mediated cleavage products are degraded by the same enzymes responsible for 
degrading the bulk cellular mRNA.  
Factors such as cell type and requirement for a transient or stable integration determine the 
method of choice to be employed. Off-target effects need to be considered when working with 
siRNAs and shRNAs. These off-target effects can be mitigated by using more than 3 
 6 
siRNAs/shRNAs for the gene of interest. [12] Additional controls include non- 
targeted/scrambled siRNAs and shRNAs. 
Several siRNA and shRNA screens have been carried out in ESCs using different readouts 
such as reporter assays, cell morphology and proliferation assays to study ESC pluripotency 
and self-renewal. [13, 14] 
1.1.3 ZFNs, TALENs and CRISPR 
Previously, Zinc Finger Nucleases (ZFNs) and Transcription activator-like effector nucleases 
(TALENs) were the most widely used targeted genome editing strategies. Both these 
technologies use engineered nucleases, i.e. artificial proteins that are composed of a 
customizable sequence-specific DNA binding domain that is fused to a nuclease that cleaves 
DNA non-specifically. [15] 
 
ZFN is a heterodimer, where each subunit consists of a zinc finger DNA binding domain and a 
Fok1 endonuclease domain. To achieve a double strand break (DSB) the Fok1 domains must 
dimerize. Each Zinc Finger (ZF) motif folds into a ββα structure that consists of ≃ 30 amino 
acids. The binding of ZF motifs to DNA takes place by the insertion of the α- helix into the 
major groove of the DNA double helix. Each zinc finger binds to a triplet within the substrate 
DNA. The amino acid  residues at -1,+1,+2,+3,+4,+5 and +6 positions to the start of the α-
helix contribute to the sequence-specific interactions between the ZF motifs and the DNA site. 
To generate ZF motifs with different sequence specificities, amino acids at these positions can 
be changed while maintaining the remaining amino acids as a consensus backbone. Several ZF 
motifs can be linked in tandem to form Zinc Finger Proteins (ZFPs) to enable binding to 
longer DNA sequences.[16]  
Specificity and affinity of ZF sets can be a challenge. To obtain adequate affinity, atleast 3 
fingers in each ZFNs are required. Addition of fingers can improve specificity as well as 
affinity , however, there is a possibility that they might mediate binding to off-target sites. 
Zinc finger technology is relatively expensive and can be tricky to synthesize. [15, 17] 
 
 The TALEN system is similar to ZFN but more flexible. TALENs too contain the Fok1 
endonuclease domain that is fused to a DNA binding domain. The DNA binding domain 
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consists of highly conserved repeats derived from transcription activator- like effectors 
(TALEs). TALEs can be designed to bind to any target DNA sequence. TALEs are proteins 
secreted by the Xanthomonas bacteria to alter transcription genes in host plant cells. The DNA 
binding domain consists of 33-34 amino acid sequence which is highly conserved. Within this 
sequence, the 12th and the 13th amino acid location is highly variable and is involved in 
specific nucleotide recognition. TALENs, like ZFNs function as dimers, thereby it requires 
two unique DNA binding domain sites in the genome with the correct orientation and spacing 
to induce a DSB. ZFNs and TALENs induced DSB can be repaired by cellular Non 
Homologous End Joining (NHEJ) or Homology Directed Repair (HDR) pathways. NHEJ-
mediated repair of a DSB in a gene results in insertions and/or deletions (INDELs) causing 
frameshift mutations that disrupts gene function. HDR repair pathway can also be exploited to 
introduce specific nucleotide modifications by supplying the double stranded DNA of interest 
as template. [15, 17]  
 
Currently, clustered regularly interspaced short palindromic repeats (CRISPR) is the most 
popular targeted genome editing tool, allowing to edit genomes with unprecedented efficiency, 
precision and flexibility. CRISPR/Cas9 is part of the bacterial adaptive immune system. Cas9 
is an endonuclease that makes a double stranded break in the DNA. The site for DNA break is 
determined by a guide RNA of ~20 nucleotides. Cas9 induced DSB are repaired via the NHEJ 
pathway. The NHEJ pathway is more error prone compared to the HDR pathway and thereby 
introduces INDELs resulting in impaired gene function. Alternatively, precise replacement 
mutations can also be made if a donor template having a mutation and homology to the 
targeted locus is supplied. [18] 
Although genome wide specificities of the CRISPR-Cas9 system has yet to be entirely 
defined, several modifications of this system such as inducible Cas9 strategies are being 
employed to provide a platform to study loss of function phenotypes. [19] 
1.1.4 Cre-loxP  
The Cre-loxP recombination strategy of Coliphage P1 provides a unique tool to manipulate the 
mouse genome. The site specific DNA recombinase Cre (cyclization recombination) is a 38 
kDa protein recognizing 34bp loxP sites and catalyzes inter and intramolecular recombination 
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between them. The loxP site consists of a nonpalindromic 8bp core region flanked by two 
palindromic 13bp sequences. [20] 
 
This strategy brings about chromosomal rearrangements between two loxP sites, referred to as 
endpoints. The recombination between two loxP sites results in chromosomal deletions, 
inversions and duplications if the loxP sites are located on the same chromosome whereas 
recombination between loxP sites located on different chromosomes results in translocations. 
To create a deletion, two regions on the same chromosome are successively targeted by 
homologous recombination using different vectors. Each vector contains a sequence for a loxP 
site. Cre recombinase expression results in the excision of DNA sequences between the loxP 
sites that have been integrated. [21] To isolate ESC clones in which successful recombination 
and deletion of genes have occurred, two non-functional halves of a selection marker gene are 
inserted in each of the vector containing the loxP site. [22, 23] For example the Conlon group 
previously used a vector that included a non-functional “split” Hprt1 cassette along with the 
first loxP site. The first loxP site was introduced into a particular locus by homologous 
recombination whereas the second loxP site and the second half of the Hprt1 cassette was 
introduced using retro-viral gene transfer. Cre recombinase expression resulted in deletion of 
chromosomal regions between the loxP sites and reconstitution of the functional Hprt1 gene. 
These recombinants were selected in Hypoxanthine-aminopterin-thymidine (HAT) medium. 
[23] HAT is a selection medium for mammalian cell culture. Aminopterin blocks DNA de 
novo synthesis which is essential for cell division. Hypoxanthine and thymidine provide the 
cells with essential components required for them to evade the blockage and proceed with the 
salvage pathway, provided the cells have functional copies of the gene encoding the HPRT 
enzyme. 
The Cre-loxP system can be used to conditionally modulate tissue-specific gene expression. 
[24] The loxP sites can be introduced around a functionally essential genomic region followed 
by a tissue-specific Cre recombinase mediated excision of the loxP flanked sequence. A 
similar strategy can be used for tissue specific overexpression of a transgene, where a strong 
expressing promoter is separated from the coding region of a gene by “stop” sequences 
flanked by loxP sites. Although in both cases Cre recombinase transgene allows spatial 
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control, once Cre expression is induced and recombination has occurred, the resultant gene 
expression is mostly irreversible. 
Animal models for spatial and temporal gene regulation have been generated by combining 
the Cre-loxP technology with inducible systems. Transgenic mice containing the gene of 
interest surrounded by loxP sites are crossed with transgenic mice that have tissue-specific 
expression of the Cre gene. The resulting mice will have the target gene deleted in tissues 
expressing Cre whereas the target gene will be present and function normally in tissues that do 
not express the Cre gene. These animals could be used to study specific tumor signature 
profiles and signaling pathways relevant to tumor supressors and oncogenes during tumor 
progression. Additionally, studies combining the Cre-loxP inducible system with RNAi have 
been used to efficiently knock down endogenous genes. [25] 
1.1.5 DELES approach  
In our laboratory, we used a Cre-loxP strategy to carry out functional studies on the mouse 
genome. [26, 27] Simon Fortier and Melanie Bilodeau employed a retro-viral based Cre-loxP 
approach to create a library of ESC clones harboring hemizygous nested chromosomal 
deletions – the DELES (Deletion in ES cells) library. This strategy was different from the Cre-
loxP strategies used by other groups as it did not use homologous recombination to deliver 
loxP sites to specific sites in the genome. The sequential addition of two retroviruses – anchor 
virus and saturation virus were used to deliver the loxP sites. The anchor virus consisted of a 
loxP site, a functional puromycin gene and a truncated ATG-less neomycin gene. The 
saturation virus consisted of a loxP site, a functional hygromycin gene and a PGK-ATG 
promoter cassette that on Cre recombination would drive the expression of a functional 
neomycin gene. (Figure 3) The retrovirus design used to generate the library is as illustrated 
below: 
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Figure 3: Retro-viral design of the primary A1 and secondary S1 Saturation virus. 
(Fortier, S., et al., Genome-wide interrogation of Mammalian stem cell fate determinants by 
nested chromosome deletions. PLoS Genet, 2010. 6(12): p. e1001241. , Permission 
obtained from Simon Fortier.) 
R1 ESCs were first infected with the A1 anchor virus to generate primary clones. The ESCs 
were infected with an infection efficiency of < 1% to achieve single provirus integration per 
cell. The puromycin resistant clones were next infected with low titer saturation virus to 
generate hygromycin resistant secondary clones. Cre-recombinase induced gene deletions 
were carried out by introducing a Cre-plasmid in ESCs through electroporation. Puromycin 
selection was again performed on G418R tertiary clones to identify clones that harbor gene 
deletions rather than other re-arrangements such as inversions and duplications. Inverse-PCR 
was used to map the deletions obtained. This library contains chromosomal deletions covering 
~ 25% of the mouse genome with a 3Mb average deletion size. The average genome coverage 
per autosome is 23% with no deletions on 19, X and Y chromosomes.  
 
To evaluate genome coverage in DELES, the cohorts of mapped deletions were categorized 
according to their molecular function based on gene ontology analysis. The 25.4% genome 
coverage of DELES includes 7083 genes, 4265 CpG islands, 128 miRNAs, 470 lincRNAs, 
241 ultraconserved elements, 648571 LINE/SINE elements and 108 cancer related genes. 
Clusters of protein-coding and non-coding elements were also deleted in this library of ES 
clones, enabling us to analyze synthetic interactions and functional redundancies between 
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family members (clones that have the anchor virus integration at the same point in the genome 
but different saturation virus integrations) of DELES. [26] 
 
 
Advantages of DELES strategy: 
 
I. Integration of the loxP sites was achieved by retro-viral gene transfer and not gene 
targeting, thereby the library was generated quickly and was less labor-intensive. 
II. Nested chromosomal deletions were generated enabling us to interrogate protein 
coding and non-coding regions associated with a phenotype. 
III. Alleles of the genes are permanently deleted and not just silenced. 
 
The DELES clones can be used to generate homozygous mutant mice to perform in vivo 
phenotypic studies of dominant and recessive mutations.  For example, in our lab, Melanie 
Bilodeau wanted to assess the in vivo biological roles of two cystatin proteins Stfa2l1 and 
Csta, the dysregulation of which has been observed in cancers such gastric cancer, head and 
neck carcinomas. To this end, she generated chimeric mice by injecting the DELES clone 7-30 
harboring a 95-kb chromosomal deletion whose deletion spanned four genes (Fam162a, 
Ccdc58, Csta and Stfa2l1) into C57BL/6J morulas and blastocysts. To achieve germline 
transmission of the mutant allele, the two chimeric mice were crossed with C57BL/6J females. 
Homozygous mutant mice were generated by intercrossing heterozygous mutant mice. PCR 
studies were conducted on the genomic DNA isolated from mouse tail clips to confirm the loss 
of the genomic regions covered by the chromosomal deletion in the homozygous mice. She 
reported that Csta and Stfa2l1 were dispensable for viability, fertility and hematopoietic 
activity. [27] 
 
Additionally, Simon Fortier exploited the DELES library to identify ES cell fate determinants. 
The goal of the study was to identify minimal genetic regions which when deleted blocked 
normal embryoid body development. LIF and BMP signaling maintains ESCs in their 
undifferentiated state in vitro. Upon removal of these signals, ESCs differentiate into 
aggregated structures called embryoid bodies (EB). These 3-D aggregate structures contain 
cells derived from the three germ layers and their formation seems to recapitulate several 
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differentiation processes observed in vivo in a spatio-temporal manner. Melanie Bilodeau 
provided evidence that within our DELES library, there is a co-relation between EB formation 
competency in vitro and contribution to chimeras in vivo. Clones which showed normal in 
vitro EB differentiation contributed to the generation of chimeras which was documented by 
coat color whereas clones with abnormal EB differentiation showed undetectable ES-derived 
contribution in the pups. She also observed that most of the clones with EB differentiation 
anomalies show formation of EBs at low frequency.[28]  
 
The criteria that a DELES family of clones should meet to determine defects in EB formation 
are: 
I. A clone should have at least 5% of seeding density: Clones were plated in two 
96-well plates in parallel, one containing semi-solid differentiation media and 
the other coated with gelatin. EBs were counted after 8 days of differentiation 
while the colonies propagated on the gelatinized surface was stained with 
methylene blue 24 hours after seeding. Metamorph software that analysed 
methylene blue stained area was used to analyze cell input that produced the 
corresponding EB number. Clones with methylene blue staining < 5% was 
excluded. This low value could be the result of a defect in proliferation, cell 
adhesion or maybe just a technical issue. 
II. An abnormal tertiary clone should produce less than 1/5th the number of EBs 
compared to the primary clone. 
III. An abnormal family should include clones with a phenotype that co-relates with 
deletion sizes. 
Simon Fortier reported that three ribosomal protein genes Rps5, Rps14 and Rps28 are haplo-
insufficient for EB formation in a p53-independent manner. [29] 
 
Disadvantages of the DELES strategy: 
I. Large deletions could involve removal of haplo-insufficient regions that are 
detrimental to ES cells. 
II. Efficiency of Cre-recombination between two loxP on the same 
chromosome decreases with increasing genetic distance. 
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III. Physical constraints such as chromatin organization might affect the 
efficiency of Cre-loxP recombination. 
 
We propose to use cDNA and BAC complementation approaches to re-introduce deleted 
regions and identify the deletions associated with an abnormal phenotype. Annotated cDNA 
libraries that can be manipulated easily are commercially available. These libraries can be 
used to identify determinants involved in relevant pathways; however, potential roles of non-
coding elements cannot be determined. Additionally, cDNA expression is mostly driven from 
a ubiquitous promoter, which may not reflect the endogenous expression level, temporally or 
specific to a cell type. To overcome these limitations, different cDNA isoforms might have to 
be tested using an inducible promoter. BAC complementation is advantageous when large 
regions (100 ~ 250kb) need to be re-introduced. They contain regulatory elements such as 
promoters and they also help in identifying non-coding elements that may be associated with 
an abnormal phenotype. However, due to their large sizes, their transfection in cells is more 
challenging. A protocol for BAC complementation has been optimized in the laboratory.[28] 
 
Since we are a lab whose focus is hematopoiesis, we would now like to use the DELES library 
to identify novel determinants of hematopoietic cell fate commitment. A preliminary 
hematopoietic screen conducted in the lab identified several DELES clones with an abnormal 
hematopoietic phenotype. To identify chromosomal regions essential for hematopoietic 
commitment, DELES clones were seeded into 96-well plates and subjected to EB 
differentiation. Embryoid bodies are able to spontaneously differentiate into cells of the three 
germ layers, including the hematopoietic cells. To test the presence of primitive hematopoietic 
cells, day 8 EBs were directly stained with benzidine – a highly selective and efficient 
procedure to demonstrate the presence of hemoglobin in EBs.  
Principle of Benzidine staining:  
The “haem” moiety of hemoglobin possesses peroxidase activity which can bring about the 
decomposition of hydrogen peroxide and liberate nascent oxygen. This nascent oxygen reacts 
with a chromogen such as benzidine to produce a blue colour product. The equation is as 
follows: 
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H2O2 +  Chromogen              haem                   oxidized chromogen + H2O 
                                                     Peroxidase activity 
The intensity of the blue colour is proportional to the amount of hemoglobin present. 
Benzidine can also be used to test the presence of erythrocytes. Erythrocytes contain an 
enzyme called catalase which also possesses peroxidase activity and catalyses the oxidation of 
hydrogen donors. [30] 
Though benzidine staining is a specific, inexpensive and a quick assay to test for the presence 
of haemoglobin, benzidine is a carcinogen. Skin absorption or inhalation of the powder has 
shown to lead to bladder cancer, therefore utmost care must be taken when handling 
benzidine. 
Using this assay, DELES clones were screened for the presence of benzidine positive EBs. 
Out of 88 clones screened, several clones exhibited abnormal phenotype i.e. % of benzidine-
positive EBs < 30 % compared to the WT R1 ESCs. Figure 4 shows the DELES families with 
the highest reduction in benzidine staining. 
 
 Figure 4: Preliminary hematopoietic screen using benzidine staining assay - The graph 
represents the percentage of benzidine positive EBs. The DELES clones were plated in duplicates in a 
96-well plate to form embryoid bodies in the absence of LIF. Direct benzidine staining was performed 
on day 8 EBs. Controls are R1 ESCs. Each dot represents a tertiary clone belonging to the family 
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mentioned on the x-axis. The grey region represents the standard deviation for the average of 
percentage of benzidine positive EBs for control R1 ESCs. 
 
To identify the stage at which hematopoietic specification is arrested in these DELES clones, 
we need to screen these clones using a hematopoietic assay that would differentiate ESCs to 
form hematopoietic cells in a stepwise manner. 
 
1.2 Hematopoiesis  
Blood cells are responsible for the maintenance of the immune system of the body. This 
relentless work requires that these blood cells have the ability to replenish themselves. The 
production and maturation of blood cells is termed hematopoiesis. [31] The Hematopoietic 
Stem Cells (HSCs) are ultimately responsible for the constant renewal of blood. [32] HSCs 
produce differentiated effector cells through a series of increasingly more committed 
intermediate progenitors. The Long-Term HSCs give rise to Short-Term HSCs which in turn 
produce multi-potent progeny (MPP) that have limited self-renewal capacity. The MPPs give 
rise to oligopotent progenitors which contain the Common Lymphoid Progenitors (CLP) and 
Common Myeloid Progenitors (CMP). CLP and CMP then give rise to lineage-restricted 
effector cells. [33] (Figure 5) 
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Figure 5: Hierarchy of hematopoietic stem cells - Illustration of the hierarchy of HSPCs 
based on self-renewal and differentiation capacity (Permission obtained, 
.Maha M. Bakhuraysah Christopher Siatskas and Steven Petratos. Hematopoietic stem cell 
transplantation for multiple sclerosis: is it a clinical reality?  Stem Cell Research & 
Therapy20167:12, (http://creativecommons.org/licenses/by/4.0/) 
 
HSC transplantation is one of the common cell-based therapies applied in clinical settings 
today. HSCs can be isolated from umbilical cord blood, peripheral blood and bone marrow but 
their use is limited due to the need for compatibility between donor and recipient and low HSC 
content. [34] Although, somatic HSCs can be expanded, after ex vivo culture their in vivo 
potential might be compromised. Pluripotent stem cells are potential sources of HSCs and can 
serve as an in vitro model to study mechanisms regulating embryonic hematopoietic 
development. Additionally, human ES cells are more amenable to genetic manipulation 
compared to the somatic HSCs that are currently used for bone marrow transplantations. 
Eventually we should be able to derive ES cell lines from patients with inherited disorders 
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using somatic cell nuclear transfer (SCNT). The genetic defects in these cell lines could be 
treated by genetic manipulation using siRNA, lentiviral and homologous recombination 
techniques and can be used to generate transplantable HSCs via in vitro differentiation.  
 
Mature hematopoietic lineages derived from human ES cells can be used for replacement 
therapies. For example, human dendritic cells (DCs) manipulated in vitro are being explored 
for the treatment of tumors and autoimmune diseases, however using current techniques, the 
number of DCs that can be isolated from patients is a limiting factor.  Generating DCs from 
human ES cells can help circumvent this problem. [35] Likewise, it may be possible to 
generate mature red blood cells from ES cells that could help in erythrocyte transfusions 
especially in cases where there is limited donor availability for rare blood cell types. [36] 
 
To enable the transit of ES-derived hematopoietic cells from bench to bedside, we will have to 
understand the 3-D microenvironment composed of stromal contacts and paracrine factors 
present in vivo during hematopoietic development and be able to recapitulate them in vitro to 
efficiently produce cells of the hematopoietic lineage. 
1.2.1 Ontogeny of hematopoiesis 
During vertebrate development, two waves of hematopoiesis can be found at distinct 
anatomical sites and they contribute to both embryonic and adult hematopoiesis. The first 
wave, known as primitive hematopoiesis, originates in the yolk sac at about E7.5-E11 [37] of 
mouse development and week 3-6 of human development. [38] At this stage, primitive 
erythrocytes are formed but the lymphoid lineages are absent. These primitive erythrocytes 
pool into blood islands soon after the start of gastrulation and these blood islands become 
enveloped by endothelial cells to form the vascular plexus of the yolk sac. [39] Primitive 
erythrocytes fulfill the functions necessary for the survival and growth of the post-
implantation embryo, however as the embryo grows, it requires more specialized cells to meet 
the demands of growth and development in later stages. To cater to this demand, the onset of 
definitive hematopoiesis occurs in the Aorta Gonad Mesonephros (AGM) and then transitions 
around E10.5 to mouse fetal liver, or between 6-22 weeks to human fetal liver. Definitive 
erythrocytes are formed during this wave. The definitive erythroid progenitors transition from 
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the fetal liver towards the newly developed bone marrow at the end of gestation. [37] The 
generation of all cells of the immune system occurs here, with the exception of T cells, which 
although originate from precursors derived from the bone marrow, develop in the Thymus. 
[39]    
                                                                                                           
 
Figure 6: Ontogeny of hematopoiesis – Illustration of the developmental ontogeny in 
humans. Reproduced with permission from The International Journal of Developmental 
Biology (Int. J. Dev. Biol.) (2005) Vol: 49 page numbers 243-250.  
1.2.2 In- Vitro derivation of hematopoietic cells  
Hematopoietic differentiation from ES cells can be induced by two types of approaches:  
a) Genetic approaches 
b) Non-genetic approaches 
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Figure 7: Methods for deriving hematopoietic cells in-vitro. (Dan S Kaufman, toward 
clinical therapies using hematopoietic cells derived from human pluripotent stem cells2009, Blood. 
Permission obtained from the journal.) 
 
Genetic approaches: Studies carried out by the Humphries and Daley group have shown that 
ectopic expression of certain genes into ES cells can be used to coax these cells to differentiate 
into HSCs/HPSCs in an in vitro system. [40, 41] 
Ectopic expression of HoxB4 in ES-derived hematopoietic cells in the presence of stromal 
cells has shown to promote expansion of hematopoietic populations with definitive HSC 
potential. [42] Studies have shown that these ESC –derived hematopoietic progenitors were 
rendered competent for engraftment and long-term multilineage reconstitution.  
In mouse ES cells ectopic expression of Cdx (family of caudal-related homeobox-containing 
transcription factors) induced mesodermal specification and enhanced HPC production. 
Expression of HoxB4 and Cdx on EB-derived cells cultured on OP9 stromal cells had a 
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synergistic effect on HPC production, enabling engraftment of all hematopoietic lineages in 
irradiated adult mice. [43] 
Recapitulating cellular interactions and paracrine effects occurring in vivo during 
hematopoietic development will help in the optimal development of ES-derived HPSC/HSCs. 
Towards this end, 3-D EB formation and stromal feeder co-culture differentiation systems are 
used in an effort to mimic the in vivo niches that support hematopoietic lineage specification. 
 
Non-genetic approaches: Different protocols are used for generating hematopoietic 
progenitors from embryonic stem cells. The most commonly used are by:  
 
 Formation of Embryoid bodies  
 Culture on supportive stromal layers (eg. OP9 stromal cells )  
Differentiation from embryoid bodies recapitulates many aspects of embryogenesis, it takes 
advantage of the principle that three-dimensional EBs can spontaneously differentiate into any 
cell type including ones of the hematopoietic lineage. [44] Gene expression analysis and 
studies on kinetics of hematopoietic lineage development within EBs have shown that it 
accurately reflects the early stages of yolk sac hematopoiesis. 
Several techniques are used to generate EBs from cultured ESCs: 1) liquid cultures in non-
adherent dishes; 2) methylcellulose or other semi-solid media; 3) hanging drop cultures and 4) 
porous scaffolds. [44] 
The 3-dimensional EB method of hematopoietic differentiation is more efficient than the 
adherent method of ESC hematopoietic differentiation on a gelatinized surface whereas the 
frequency of hematopoietic progenitors obtained using any method of EB culture is similar. 
[45] Liu group has shown that dynamic conditions and biomaterial-based scaffolds enhance 
the efficiency of ESC differentiation. To evaluate the spontaneous differentiation of ESCs, 
EBs can be cultured in ESC differentiation media without cytokines. In the absence of 
cytokines, cells within the EB are able to secrete proteins such as CSF, IL-3 and Epo to 
support the development of early erythroid and macrophage precursors. [46] To induce the 
differentiation of a specific hematopoietic lineage , single-cell suspension of EBs are directed 
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to differentiation media or methylcellulose culture containing hematopoietic cytokines such as 
SCF, GM-CSF, Epo and interleukins such as IL-1, IL-3,IL-4 and IL-6. [46] The emergence of 
hematopoietic cells in this system can be tracked through gene expression analysis of lineage 
specific markers and immunohistochemistry. Additionally, single-cell suspensions obtained by 
dissociating EBs with trypsin or collagenase can be analyzed by flow cytometry. [47, 48] 
Within the EBs a transient primitive erythroid population emerges first. The lymphoid 
progenitors and the HSCs are not generated in the early stages of EB hematopoiesis, further 
reflecting yolk sac hematopoiesis. Though lymphoid progenitors are not generated in the early 
stages of EB differentiation, B and T cell lineages have been generated when ES cells are 
cultured for extended periods of time in the presence of stromal cells. [45] 
The bone marrow stroma acts as a three dimensional framework for hematopoiesis. It contains 
a heterogeneous population of cells including mesenchymal stem cells (MSCs) that play an 
important part in the bone marrow niche. It helps in the interactions of hematopoietic stem and 
progenitor cells (HSPCs) with the extra-cellular molecules and soluble factors that are 
essential for survival and proliferation. [49] With this in mind, primary stromal cell lines were 
used as feeders to expand HSPCs ex-vivo. The different stromal lines commonly used are OP9 
[50], S17 [51] and AM20-1B4 [52]. OP9 is a cell line established from mouse calvaria and 
lack functional macrophage colony-stimulating factor (M-CSF). The absence of M-CSF 
enhances hematopoietic differentiation by minimizing preferential differentiation towards the 
monocyte-macrophage lineage. [53, 54] ESC – derived erythroid, myeloid and B- lineage cells 
are obtained using OP9 stroma without the addition of exogenous growth factors; however 
cytokine supplementation influences lineage output. The onset of definitive hematopoiesis and 
expansion of HSCs takes place in the AGM region; cell lines derived from the AGM region 
like UG26-1B6 are also used with the aim of providing signals unique to this micro-
environment to help with the hematopoietic differentiation. [55] 
Culturing on feeder layers have resulted in successful hematopoietic differentiation, however, 
use of cells in human therapy requires their culture conditions to be defined and “animal-free”. 
Serum contains several undefined components and we cannot exclude the contamination of the 
desired hematopoietic cells with the feeder cells or antigens transmitted by the feeder cells 
even with processes such as cell sorting. Also, since the serum contains undefined factors, the 
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efficiency of the differentiation assay may differ from batch to batch of the serum used and 
call into question the robustness of the differentiation protocol. [56] 
To overcome these issues, I have adopted a “serum-free, feeder-free” hematopoietic 
differentiation protocol published by the Keller group. [57] The hematopoietic cells derived 
here are free of undefined components and interactions.  
Growth factors and cytokines constitute an important part of the regulatory niche; therefore it 
is important to know the effect of different cytokines on the developmental pathways in order 
to nudge the differentiation of mESCs to the desired lineage. In the protocol I set up in the lab, 
Wnt3a, Activin A, BMP4 and VEGF were used during appropriate time windows to bring 
about lineage specification step by step. 
Transforming Growth Factor – β (TGF-β), Bone Morphogenetic Protein 4 (BMP4) and 
Activin are members of the TGF-β family of ligands that signal though SMAD pathways to 
regulate hematopoietic stem and progenitor cells (HSPCs) during hematopoiesis. Upon 
binding of TGF- β ligands to their receptors, the receptor regulated R-SMADs get activated 
and bind to SMAD4. This complex translocates to the nucleus and activates several target 
genes responsible for regulating many signaling pathways. BMP4 is a morphogen that induces 
ventral mesoderm and promotes hematopoietic commitment. [58] Apart from its role in 
specification of HSC during development, it also regulates proliferation of adult HSCs [59] 
and addition of BMP4 in culture has shown to increase the percentage of CD45+ population. 
[60] BMPs are mainly produced by the osteoclasts in the HSC niche. [61] 
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Figure 8: SMAD signaling at different stages during hematopoietic commitment - SMAD 
signaling regulates HSC specification and its subsequent expansion critically at different 
stages (Jonas Larson et al, 2005, Oncogene. Permission obtained from the journal.) 
 
While BMP4 appears to have a crucial instructive role for the induction and formation of 
blood cell precursors, other factors are also involved in their regulation and subsequent 
expansion. Vascular Endothelial Growth Factor (VEGF), a KDR ligand is known to induce the 
proliferation and differentiation of the BMP4-induced hematopoietic progenitors. [62, 63] 
VEGF and its homologue PIGF produced by HSCs and erythroblasts influence the bone 
marrow microenvironment in many ways. They induce bone marrow endothelial cells to 
express E- selectin and thereby play an important role in HSC migration. Additionally they 
also act as survival and proliferation factors as VEGF-R1 and VEGF-R2 are expressed on 
immature HSCs that possess repopulating capacity. [64] Studies have shown that elimination 
of VEGF genes leads to decreased HSC survival, colony forming ability and hematopoietic 
repopulation following transplantation. [65] VEGFA is known to promote HSC survival, 
whose expression levels are dramatically increased in hypoxic conditions. [66] 
The Wnt pathway has a varied influence on hematopoiesis. This pathway has 19 different 
ligands and about 10 different receptors. The different receptor-ligand combination can result 
in either canonical or non-canonical downstream signalling. [33] Evidence that Wnt signaling 
plays a role in hematopoiesis came from studies demonstrating the presence of Wnt ligands 
and receptors in different hematopoietic anatomical sites such as murine yolk sac, aorta-
gonad-mesonephros, fetal liver and adult bone marrow. [33] Studies have shown that the 
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addition of Wnt3a in mESC cultures increases the generation of hematopoietic  cells and 
promotes proliferation of hematopoietic progenitors. Wnt signaling not only plays a role in 
HSC survival and proliferation but is also involved in the maturation and maintenance of 
lymphoid progenitor cells such as pro-B cells, pre-B cells, immature thymocytes and mature 
T-cells. [67] 
As ES cells differentiate towards the hematopoietic lineage, they express several transcription 
factors in an orderly manner. Some of the transcription factors and surface markers that can be 
used to assess the differentiation at specific stages are illustrated in Figure 9.  
 
Figure 9: Lineage-specific gene markers used to assess hematopoietic differentiation 
from ES cells. 
 
1) Brachyury (T) – It is a transcription factor that binds to a specific DNA palindromic  site. 
Binding occurs through a region called the T-box present in the N-terminus region. On 
binding, Brachyury regulates the transcription of several genes required for mesoderm 
differentiation. Brachyury expression is critical for posterial mesoderm development in the 
mouse. During development, Brachyury expression is observed in early gastrulae next to 
primitive streak cells destined to form the mesoderm. T-/- embryos die at E.10 due to the 
absence of a notochord and allantois. [68] 2) CD41 – expression of CD41 in murine 
development marks the onset of definitive hematopoiesis. CD41 expression precedes that of 
CD45. In adult hematopoiesis CD41 expression is associated with megakaryocytes and also 
plays a role in platelet function. Hematopoietic cells emerge from a CD41+ population; these 
cells then express CD45 on maturation. It can thus be said that in murine development, the 
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expression of CD41 separates the hemogenic endothelium from the hemangioblast - which is 
the common precursor for hematopoietic and endothelial cells. [69] 3) Runt-related 
transcription factor 1 (RUN1X) plays a crucial role in definitive hematopoiesis. It is involved 
in the transition of hemogenic endothelial cells to hematopoietic cells. [70] 4) GATA-1 and 
GATA-2 are members of the GATA family of transcription factors. GATA-1 is involved in 
erythroid development and is highly expressed in erythroid cells whereas GATA-2 is 
expressed on early hematopoietic progenitors and plays a role in HSC production in the AGM 
region and HSC proliferation throughout the ontogeny. [71, 72] 5) Beta-Globin is part of the 
hemoglobin protein and is involved in erythropoiesis. Mutations in the β-globin gene results in 
blood disorders such as β-thalassemia and anemias such as sickle cell anemia. [73] 6) C-kit – 
also known as cytokine tyrosine kinase receptor. C-kit, the receptor for SCF, is present on 
HSCs and the stromal cells in the bone marrow secrete SCF. Upon binding to the receptor, the 
receptor homo-dimerizes and auto-phosphorylates at tyrosine residues activating pathways 
responsible for hematopoiesis and HSC maintenance such as JAK/STAT and RAS/ERK 
pathways. C-Kit is not essential for the expansion of HSCs in fetal development, although it 
plays an important role in maintaining the long-term steady state HSCs in adult BM. It also 
promotes HSC proliferation when in synergy with other hematopoietic cytokines. [74] 7) 
CD45 is a pan-hematopoietic marker expressed on most hematopoietic cells except 
erythrocytes and platelets. [75, 76] Due to variable exon splicing, different CD45 isoforms are 
expressed by different subsets of hematopoietic cells. For example  CD45RA is expressed by 
naïve/resting T cells and medullary thymocytes and CD45RO is expressed on 
memory/activated T cells and cortical thymocytes. [77] 
Goal, Hypothesis and Objectives:  
Goal: As mentioned previously, one of our interests in the lab is to take advantage of the 
DELES library to identify genes or DNA fragments that are required for hematopoietic cell 
fate. Using clones from the DELES library, we expect to reveal several haploinsufficient and 
synthetic loci that contribute to the differentiation of ES cells to the hematopoietic lineage. 
Before this is possible we need to establish a robust hematopoietic differentiation assay which 
could be exploited to rescreen the DelES collection. 
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My hypothesis is that the in vitro differentiation assay developed in Dr. Keller’s laboratory 
could be imported in our laboratory and be used to better characterize the hematopoietic 
phenotype of DelES clones.  
 The objectives of my project are to : 
 Establish in the laboratory a hematopoietic differentiation assay from mouse ES 
cells which will serve as a more stringent screen to observe hematopoietic 
commitment of the candidate DELES clones. This will involve optimizing Q-RT-
PCR and FACS parameters for this assay. 
 Validate candidate DELES clones identified in the preliminary hematopoietic 
screen using this assay to monitor where the differentiation arrest is occurring. 
In a secondary project I will test if a human haploid cell line, KBM-7, can be exploited using 
the DELES approach to create a library of clones comprising random chromosomal deletions. 
KBM-7 is a human near haploid Chronic Myeloid Leukemia (CML) cell line. Haploid cell 
lines such as the KBM-7 cell line serve as an excellent model system to carry out functional 
screens as the phenotype of the mutated allele will not be masked by the allele on the other 
homologous chromosome.[78] 
This library of KBM-7 clones containing nested chromosomal deletions can serve as a 
platform on which various studies to understand the mechanisms contributing to leukemia 
development and treatment of leukemia can be conducted. For example, in our lab, this library 
will be used to delineate the molecular activities of potential anti-leukemic drugs as well as 
allow me to identify molecular signaling pathways that, when genetically disrupted, can confer 
resistance to novel and existing drugs.[79] 
 
 
 
  
2. Materials and Methods 
Embryonic Stem Cell maintenance and differentiation 
R1 ESCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) in the presence 
of LIF and serum. Hematopoietic differentiation of mESCs was induced using the protocol 
published by Keller et al. (2012). To set up the differentiation assay, the ES cells previously 
grown on MEFs were split on dishes coated with 0.1% gelatin. ESCs were treated with trypsin 
and seeded at a density of 2.5x10^5/mL in a serum-free differentiation medium (75% IMDM, 
25% Ham’s F12, supplemented with 1% N2, 0.5% B27, 0.05% BSA, 50 µg/mL ascorbic acid, 
4.5 x 10-4 M 1-thioglycerol, 2 mM glutamine and penstrep) for 48 hours in 60mm bacterial 
dishes. The embryoid bodies formed were dissociated using 0.25% Accutase for 5 minutes at 
37 ̊ C and then re-aggregated at the same density in the serum free media containing 3ng/mL 
Wnt3a and 1ng/mL Activin A for an additional 48 hours to induce mesoderm differentiation. 
The aggregates formed were once again dissociated and re-suspended in the serum free 
medium, this time in the presence of 1ng/mL BMP4 and 5ng/mL VEGF to induce 
hematopoietic commitment. Recombinant Mouse Activin A (R&D systems, Ref # 338-AC-
010), recombinant mouse Wnt3a (R&D systems, Ref # 1324-WN-002), recombinant human 
BMP-4 (R&D systems. Ref # 314-BP-010) and recombinant human VEGF165 (R&D systems, 
Ref # 293-VE-010) were used. 
 
Embryoid body differentiation 
To improve the differentiation efficiency by getting rid of the MEFs, ES cells were split on 
0.1% gelatin prior to the differentiation. A 5X Master mix of the differentiation media was 
prepared containing IMDM+glutamine, 15% heat-inactivated Fetal Calf Serum, 50µg/mL 
Ascorbic acid, 5% PFHM II , 0.3Mm 1-thioglycerol and Penstrep. To prepare the semi-solid 
media, half the media volume was replaced with methylcellulose. Tubes containing 
methylcellulose and differentiation media were vortexed to attain a homogeneous formulation. 
The ES cells were trypsinized for 5 minutes at 37 ̊ C and neutralized using the differentiation 
media. ESCs were seeded at a density of 1250cells/mL in 60mm bacterial- grade tissue culture 
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dishes. After adding the cells into the semi-solid media, the cells were mixed manually. 5mL 
syringes and blunt needles were used to slowly transfer the mixture to the dishes. Each dish 
was placed in a larger dish humidified with sterile water. 
 
Benzidine Staining Assay 
A benzidine (Sigma, Cat # B1883-100mg) stock solution of 3% was made by diluting 4, 4’-
Diaminobiphenyl in 90% glacial acetic acid and 10% water solution. A fresh working solution 
of 1 part benzidine stock solution, 1 part hydrogen peroxide (Sigma, Cat # H3410) and 5 parts 
of sterile water was prepared prior every staining. Day 8 embryoid bodies were stained for the 
presence of hemoglobin by adding 0.2mL of the working solution per 2mL of methylcellulose 
culture directly onto the dish. 
 
RNA Extraction 
The cell suspension from one 60 mm dish was collected and spun down at 800rpm for 5 
minutes. Media was aspirated and the cells were washed with PBS and spun down again. The 
PBS was aspirated and the cell pellet was re-suspended in 1mL TRIzol reagent (Life 
Technologies, Cat # 15596-026). The samples were stored at -80 ̊C for subsequent RNA 
isolation. 
 RNA Isolation: 
RNA was extracted from TRIzol stored samples according the manufacturer’s instructions. 
 Measurement of RNA concentration : 
 The concentration (260nm) and purity of RNA was assessed using an Implen 
nanophotometer. 
cDNA synthesis 
1.5 µg of RNA was used to synthesize DNA using MMLV-RT (Invitrogen, Cat # 28025-013) 
according to manufacturer’s instructions. The following program was used: 
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Table 1: cDNA synthesis program 
Temperature Time 
25  ̊C 10 minutes 
37  C̊ 50 minutes 
70  ̊C 15 minutes 
 
QRT-PCR 
Here the DNA was further quantified and simultaneously amplified. The qRT-PCR was carried 
out using TaqMan® Fast Advanced Master Mix (Applied Biosystems, Cat # 4444558) 
 Master Mix preparation : 
A master mix was prepared and used at a final volume of 8.5µL for each well of a 384- well 
plate. 
Table 2: Composition of Master Mix for qRT-PCR. 
Component Volume (µL) 
Taqman Mix 5 
Primers (F+R) 0.1 
Exiqon probe 1 
Water 2 
 
o cDNA (1/5 dilution) = 2µL was used for each reaction. 
The primers used for qRT-PCT were obtained from the genomic platform at IRIC. 
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Table 3 – Sequence of primers used for qRT-PCR 
GAPDH  F - TGTCCGTCGTGGATCTGAC 
R - CCTGCTTCACCACCTTCTTG 
HPRT F -TCCTCCTCAGACCGCTTTT 
R-CCTGGTTCATCATCGCTAATC 
OCT 4 F-GAGGCTACAGGGACACCTTTC 
R-GTGCCAAAGTGGGGACCT 
T F-CGACCACAAAGATGTAATGGAG 
R-CCAGCACCAGGAACAAGC 
CD41 F-TGCTGCTGACCCTGCTAGT 
R-GTCGATTCCGCTTGAAGAAG 
C-KIT F-GGAGCCCACAATAGATTGGTAT 
R-CACTGGTGAGACAGGAGTGG 
RUNX1 F-CTCCGTGCTACCCACTCACT 
R-ATGACGGTGACCAGAGTGC 
GATA2 F-TCACCCCTAAGCAGAGAAGC 
R-TGTGGCACCACAGTTGACA 
β-GLOBIN F-TGCATGTGGATCCTGAGAAC 
R-AGCAGGGGTGAAATCCTTG 
CD45 F-AGTTAGTGAATGGAGACCAGGAA 
R-TCCATAAGTCTGCTTTCCTTCG 
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o Calculation for relative fold expression : 
For each reaction, the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and Hypoxanthine guanine phosphoribosyltransferase (HPRT) were used as 
internal primer controls. Relative fold expression was calculated by subtracting Ct 
(GAPDH/HPRT) values from the Ct (sample) values. The resulting values were used to 
calculate fold expression by comparing it to the experimental control which in my case 
was day 0 of differentiation. The following formula was used to calculate relative fold 
expression: 
ΔΔCt = ΔCt (sample) – ΔCt (Day 0) 
Relative fold expression = 2^- ΔΔCt. 
The qRT-PCR program used is as follows: 
Table 4: qRT-PCR program̊ 
 Temperature Time Stage 
Step 1 95  ̊ C 20 seconds Hold stage 
Step 2 95  ̊ C 1 second PCR stage 
60  ̊ C  20 seconds 
Number of cycles = 40 
     Flow cytometry 
Cells from a dish were collected and spun down at 800rpm for 5 minutes. This was 
followed by washing with PBS for 5 minutes at 800rpm. The cell pellet was treated with 
500µL of Accutase at 37 ̊ C for 5 minutes. The Accutase was neutralized with 7mL of 
serum-free differentiation media. Antibody staining was conducted for 1x10^5 cells in 
100µL media for 20 minutes. The cells were then washed by adding 2mL PBS and spun at 
800 rpm for 5 minutes. The PBS was aspirated leaving behind 50µL. The samples were 
read using BDFACS Canto. The antibodies used were anti-mouse APC/Cy7 CD45.2 
(BioLegend, Cat # 109824) and anti-mouse APC Ter-119 (BioLegend, Cat # 116212). To 
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gate out dead cells, Molecular probes Live/dead Fixable Violet Dead cell Stain Kit was 
used (Life technologies, Ref # L3L955). 
Methylcellulose preparation used in viral stock titration 
MethoCultTM (StemCell Technologies Inc.) 
 Methylcellulose preparation used to plate wild type KBM-7 cells : 
Table 5: Methylcellulose Mix 
Components Volume for 30mL prep Final Concentration 
Methylcellulose stock 2% 17mL 1.13% 
IMDM 6.4mL  
FBS – Heat Inactivated 6mL 20% 
Glutamine (200Mm) 300µL 2mM 
Β- Mercaptoethanol ( 10-2  ) 300µL 10-4 M 
 
 Methylcellulose + cytokines preparation used to plate wild type KBM-7 cells and 
titrate  MSCV- GFP and A1 viral stock: 
Table 6: Methylcellulose Mix with cytokines 
Components Volume for 30mL prep Final Concentration 
Methylcellulose stock 2% 17mL 1.04% 
IMDM 4.5mL  
FBS – Heat Inactivated 6mL 20% 
Glutamine (200Mm) 300µL 2mM 
Β- Mercaptoethanol ( 10-2  ) 300µL 10-4 M 
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Deionized BSA, 30% stock 1mL  
Holo-transferrin ( 30 mg/mL) 0.192µL  
SCF ( 60ng/µL) 60µL   100 ng/mL 
1L-3 ( 80ng/µL) 4µL 10 ng/mL 
GM-CSF ( 300ng/µL) 1µL 10 ng/mL 
EPO ( 280 U/mL) 320µL 3 U/mL 
IL-6 (10ng/µL) 30µL 10 ng/mL 
TPO ( 8ng/µL) 200µL 50 ng/mL 
Transfection 
HEK293 (expressing stably VSV-G envelope and gag and pol genes) were cultured to be 75 - 
80% confluent on the day of transfection. For transfection in a 10 cm dish the following mixes 
were prepared: 
Mix A: 
o DNA – 20 µg 
o Gag-Pol - 5µg 
o VSV-G - 5µg 
The volume was made up to 1mL with Opti-MEM. 
Mix B: 
o Lipofectamine - 80µL 
o Opti-MEM - 1920µL 
The Mix B was incubated for 5 minutes at room temperature. 1mL of A and B were mixed and 
incubated for 20 minutes at room temperature. The media from the plates were collected and 
fresh media (DMEM + 10% Heat inactivated FBS) was added very slowly. 5µg/mL of 
tetracycline was added to the plate. 
The cells were incubated for 5 hours, after which the media was changed and fresh media was 
added. The viral supernatant was harvested after 48 hours and continued for 5 days. 
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 Formula to calculate viral titer: 
 Titre (TU/mL)  = {(F x Cn)/V} x D.F 
Where, 
F – Frequency of target cells (GFP+ cells) or {colonies (+ puromycin) / colonies (- 
puromycin)}y 
Cn – the total number of target cells infected 
V – The volume of the inoculum 
D.F – dilution factor 
 
 
 
 
  
3. Results 
3.1.1 Establishment of a hematopoietic differentiation protocol. 
In the lab, we had conducted a preliminary hematopoietic screen using a benzidine staining 
assay to test the hematopoietic phenotype of the DELES clones. Benzidine is a compound that 
stains blue in the presence of hemoglobin. 5000 ES cells were plated in a 60mm dish and 
allowed to differentiate to EBs for 8 days.0.4mL of working benzidine solution was prepared 
as described in the Material and Methods section and was used to directly stain EBs to test for 
the presence of hemoglobin. The percentage of benzidine-positive EBs was calculated using 
the formula:  
                    (Number of EBs that stained blue in the presence of benzidine )  x 100 
                                                 Total number of EBs 
 Based on this preliminary assay, we identified several DELES clones that showed an 
abnormal hematopoietic phenotype. However, since this assay only tested for the presence of 
hemoglobin, we needed to establish a more stringent (and more sensitive) screen to study 
stepwise hematopoietic commitment of the candidate DELES clones using q-PCR and flow 
cytometry techniques. To achieve this, I worked on setting up a feeder-free, serum-free 
differentiation assay published by the Keller group [57] .  
 
Figure 10 illustrates the differentiation protocol. Based on literature review, I decided to 
examine the expression of hematopoietic genes such as CD41, C-KIT, RUNX1, GATA1, β-
globin1 and CD45, which will provide a good insight on hematopoietic commitment and 
differentiation. 
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Figure 10: Schematic of the hematopoietic differentiation assay.  R1 ESCs split previously 
on 0.1% gelatin were trypsinized and re-suspended in a serum-free differentiation media at a 
density of 2.5x10^5 cells/mL for 48 hours to form EBs. Day 2 EBs were dissociated and re-
aggregated in the presence of Wnt3a and Activin A to form primitive streak-like cells. Day 4 
cell aggregates were dissociated and re-suspended in the presence of BMP4 and VEGF for an 
additional 48 hours to form primitive blood progenitors. 
 
3.1.2 Kinetics of the hematopoietic differentiation. 
Lineage commitment upon directed differentiation is associated with a decline in pluripotency 
and upregulation of lineage specific genes. Here, the differentiation time course was 
monitored by qRT-PCR. 
 
To induce differentiation, different growth factors and cytokines were added in the appropriate 
time windows as displayed in Figure 10. The impact of these signals on differentiation can be 
seen by the decline in OCT4 expression (Figure 11) and concomitant upregulation of the 
mesodermal marker Brachyury (T) which peaks by day 5 and then declines over the next few 
days. Expression of hematopoietic genes like CD41, C-kit, RUNX1 and GATA1 is not 
detected until day 4 and is induced from day 5. This trend is expected, as in the protocol I am 
using, it is on day 4 of differentiation I add cytokines and growth factors that drive 
hematopoietic differentiation. CD45 and β-globin 1 expression is also induced, indicating 
hematopoietic differentiation and erythroid lineage commitment. 
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Figure 11: Kinetics of hematopoietic differentiation. – Sequential expression of OCT4, T 
and hematopoietic genes CD41, C-KIT, RUNX1, GATA2, CD45 and β-GLOBIN1 monitored 
by qRT-PCR. GAPDH and HPRT housekeeping genes are used as internal control. Relative 
Quantification (RQ) value is calculated using day 0 as a reference (described in the material 
and methods section), it depicts the expression of the target gene on a given day compared to 
its expression on day 0 of the differentiation assay. N=3, Error bars represent S.D 
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From the literature, we know that during hematopoietic ontogeny, mesodermal cells first 
acquire CD41 expression upon hematopoietic commitment. CD41 is one of the earliest mouse 
markers representative of hematopoietic commitment. As the cells continue to differentiate 
from hematopoietic stem cell (HSC) to a more progenitor-like fate, they gain CD45 expression 
as well, which is maintained in all cell lineages except erythrocytes. We observe a similar 
trend in our assay. We also know that the first lineage to emerge during primitive 
hematopoiesis is the primitive erythrocytes; thereby the presence of β-globin1 expression at 
earlier time points is as expected. From the above results, it was concluded that the 
hematopoietic differentiation assay was able to induce the expression of hematopoietic genes 
CD41, C-KIT, RUNX1, GATA2, CD45 and β-GLOBIN1 in a reproducible manner. 
  
Studying the kinetics of the differentiation assay, I decided to choose day 6 (a time point 
where hematopoietic differentiation is just being induced) and day 8 (a later time point after 
the induction of hematopoietic differentiation) time points to conduct FACS analysis of 
hematopoietic surface markers CD45 (pan-hematopoietic marker, expressed in all 
hematopoietic cells except in erythrocytes) and Ter-119 (expressed on all erythroid cells). The 
first step in this direction was to evaluate the optimal concentration of the respective 
antibodies to be used in our assay. 
3.1.3 Titration of CD45 and Ter-119 antibodies. 
The process of identifying the optimum concentration of antibody to use for a given assay is 
known as titration. To titrate antibodies it is important that we use a cell population that 
expresses the target of interest. In our case, the R1 cells are Ly 5.2, I used cells isolated from 
the spleens of two mice – Pep3B and C57BL/6 which are Ly5.1 and Ly5.2 cells, respectively, 
to get a good positive and negative peak while titrating the antibodies. 
Cells were isolated from the entire spleen of a mouse of each genetic background. The total 
numbers of cells were pooled together. An aliquot of 100,000 cells were taken and used as a 
positive control for the markers CD45 and Ter-119. Serial dilution of the antibodies was 
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prepared as to get five different concentrations of the antibodies -1/25, 1/50, 1/100, 1/200 and 
1/400. 
The hematopoietic system has a well-defined differentiation cascade comprised of distinct 
intermediates connecting the differentiation of naïve hematopoietic stem cells into mature 
hematopoietic cells. 
In FACS, a scatter plot of FSC vs SSC will give us the distribution of cells based upon size 
and granularity respectively. From literature, and experience we expect to see the distribution 
of blood cells in a SSC vs FSC FACS plot as below: 
 
 
Figure 12- Illustration of the distribution of different blood cell types on a SSC vs FSC 
FACS plot. 
(https://www.researchgate.net/post/What_FACS_parameters_to_consider_when_I_want_to_c
ount_MEFs_cells_and_differentiate_between_live_and_dead_cells) 
 Ter-119 Antibody Specificity: 
The following analysis was conducted to test whether the Ter-119 antibody is specific for 
erythrocytes as expected. 
 
 40 
 
 
 
Figure 13: Ter-119 Antibody titration - Spleens isolated from C57BL/6 and Pep 3B mice 
were used to as positive control for the titration of Ter-119 antibody. A and B panels show the 
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antibody specificity for the 1/25 and 1/200 dilution of the antibody respectively. The living 
population was first gated on the SSC-FSC plot. The TER-119 + population correspond to the 
region where the erythrocytes are expected on the SSC-FSC FACS plot. C) Figure showing 
the separation of negative and positive population for different Ter-119 antibody dilutions. D) 
Graph showing the Mean Fluorescent Intensity for different Ter-119 antibody dilutions. 
The plots on panel A and B shows that, with higher antibody concentration I get a better 
separation of the positive and negative populations. I also see that the TER-119 positive 
population corresponds to a region where we expect to see erythrocytes in a SSC vs FSC plot. 
(Figure 12) 
 CD45.2 Antibody Specificity : 
The following analysis was conducted to test if the CD45.2 antibody being used is specific for 
cells expressing CD45.2 – hematopoietic cells except erythrocytes.  
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Figure 14: CD45.2 Antibody titration - : Spleens isolated from C57BL/6 and Pep 3B mice 
were used as positive control for the titration of CD45.2 antibody. A and B panels shows the 
antibody specificity for the 1/25 and 1/200 dilution of the antibody respectively. The living 
population was first gated on the SSC-FSC plot. The CD45.2 + population correspond to the 
region where the hematopoietic cells are expected on the SSC-FSC FACS plot. C) Figure 
showing the separation of negative and positive population for different CD45.2 antibody 
dilutions. D)  Graph showing the Mean Fluorescent Intensity for different CD 45.2 antibody 
dilutions. 
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Given that in a titration assay, the optimal antibody concentration will be the one resulting  in 
specific staining of the target population and the best separation of the positive and negative 
populations , I used the 1/25 dilution of TER-119 and CD45.2 for my flow cytometry assays.  
 
To determine the efficiency of the differentiation assay, I assessed the percentage of CD45+ 
and TER-119+ population in the differentiation cultures. On FACS analysis, I observed about 
10% CD45+ cells on day 6 which slightly increased to 15% on day 8 whereas the percentage 
of  TER-119+ cells  was about 1.5% on day 6 which increased to 30% on day 8. ( Figure 15).  
 
 
Figure 15: FACS analysis of the differentiation assay - Percentages of CD 45.2+ and TER-
119 + populations on day 6 and day 8 of the hematopoietic differentiation assay. N=2, Error 
bars represent S.D. 
 
From this result , I concluded that the readout fror CD45+ and Ter-119+ populations  on day 6 
and day 8 time points of the differentiation assay will be used for screening the hematopoietic 
phenotype of the DELES clones. 
Q-PCR and FACS results indicated that hematopoietic differentiation of R1 ESCs was 
occurring and the differentiation was skewed to the erythroid lineage. The assay I set up is 
robust and will be used to accurately screen the hematopoietic potential of the candidate 
DELES clones. 
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3.2 Validation of the DELES clones using the hematopoietic 
differentiation assay. 
3.2.1 Preliminary screen of DELES library identified clones having reduced 
hematopoietic potential. 
In the preliminary hematopoietic screen conducted using benzidine assay (Figure 16), 
reduction or absence of benzidine coloration in some clones strongly suggests the deletion of 
gene(s) important for hemoglobin biosynthesis and/or deletion of chromosomal regions 
playing a critical role in hematopoietic commitment. 
 
Figure 16: Benzidine Staining Assay - The graph represents the percentage of benzidine 
positive EBs. The DELES clones were plated in duplicates in a 96-well plate to form 
embryoid bodies in the absence of LIF. Direct benzidine staining was performed on day 8 
EBs. Controls are R1 ESCs. Each dot represents a tertiary clone belonging to the family 
mentioned on the x-axis. Error bars represent the standard deviation for the average of 
percentage of benzidine positive EBs for each family. The clones selected for validation are 
red dot – 5241.16, green dot – 5241.09, yellow dot – 5241.42, pink dot – 5035.10 and orange 
dot – 5035.41. 
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Out of the 7 families which had clones exhibiting reduced benzidine staining (Figure 4), I 
decided to pursue the 5241 and 5035 families further. To confirm the robustness of the 
benzidine staining assay, I repeated the assay for the two families in a larger 60mm dish 
format. 
3.2.2 Validation of the 5241 and 5035 DELES families. 
The 5241 family contains nested deletions in chromosome 15. Within this family, I selected 
one primary clone (clone having only the anchor virus integration and no deletions) – 5241 1 ̊ 
and three tertiary clones (clones having the same anchor virus integration and different 
saturation virus integrations.)  – 5241.16 (Rims2), 5241.09 (Klf10, Azin1, Atp6v1c1, Fzd6, 
Cthrc1, Stc25a32, Wdsof1, Rims2) and 5241.42 (Zfp706, Grhl2, Ncald, 4930447A16Rik, 
Rrm2b, Ubr5, Odf, Klf10, Azin1, Atp6v1c1, Fzd6, Cthrc1, Stc25a32, Wdsof1, Rims2) with 
increasing deletion sizes as shown in Figure 17.  The three tertiary clones were selected based 
on their chromosomal deletion size and their high proliferation state as determined by Ki67 
staining. High proliferation state clones were selected as they can be propagated easily. Clones 
5241.16, 5241.09 and 5241.42 had 99.3%, 94.3% and 93.4% of cells positive for Ki67 
respectively. 
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Figure 17: Representation of the nested chromosomal deletions in family 5241 -The 
deletions were mapped using I-PCR. The location of the anchor virus integration (green 
arrow) is Chr 15: 39,076,241. The 1st, 2nd and 3rd yellow arrows indicate the selected clones 
5241.16, 5241.09 and 5241.42 having 1, 8 and 15 genes deleted in them respectively. 
(http://bioinfo.iric.ca/deles/Families) 
 
Benzidine staining assay was performed on day 8 of EB differentiation. The percentage of 
benzidine positive EBs in clones 5241.16, 5241.09 and 5241.42 were 5% ± 0.9, 4 % ± 0.3 and 
10%±1 respectively compared to the primary clone which was 13 % ±1. (Figure 18, left panel) 
We observed that the number of EBs formed for each of the 5241 clones and the R1 ES cells 
are comparable (Figure 18, right panel). As mentioned in the literature review, to state a 
tertiary clone has a defect in EB formation, it should meet the following criteria:  
a) A clone should have at least 5% of seeding density. 
b) An abnormal tertiary clone should produce less than 1/5th the number of 
EBs compared to the primary clone. 
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c) An abnormal family should include clones with a phenotype that co-
relates with deletion sizes. 
5241 tertiary clones do not meet these criteria.  
 
 
Figure 18: Embryoid body formation and Benzidine staining assay of 5241 family : 5241 
clones were seeded at a density of 1250cells/mL in semi-solid differentiation media and 
allowed to form EBs.  5241 1° is the primary clone without any chromosomal deletions. 
5241.16, 5241.09 and 5241.42 are tertiary clones containing 1, 8 and 15 genes deleted in them 
respectively. Day 8 EBs were stained with benzidine and scored, n=3. Error bars represent S.D 
 
The benzidine staining results showed that there is indeed reduced benzidine coloration among 
the tertiary clones compared to the primary clone.  I also observe a reduction in the percentage 
of benzidine staining between the control primary clone and the R1 ESCs, here I hypothesized 
that the infection and integration of the primary anchor virus may itself have contributed to the 
reduced hematopoietic potential of this family. An interesting result here is that the tertiary 
clone 5241.16 containing a single gene (Rims2) deletion already exhibits an abnormal 
hematopoietic differentiation. Though I see a reduction in the number of EBs formed in clone 
5241.16, I do not see the same extent of reduction in clone 5241.09 and 5241.42 (criteria c) 
although I do observe the same extent of reduced benzidine staining in clone 5241.16 and 
5241.09. Therefore, I suggest that the reduction in the percentage of benzidine positive EBs 
observed in these clones are not due to defects in the formation of embryoid bodies. 
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The Rims2 gene is highly expressed in reproductive tissues such as testis and moderately 
expressed in hematopoietic myeloid and lymphoid cells. Mice homozygous for this deletion 
have reduced body size, aberrant insulin granule exocytosis, impaired secretion of hormones 
associated with glucose homeostasis, however, their hematopoietic phenotype is 
undetermined. 
Next, I proceeded with the validation of another DELES family clone – 5035 that looked 
interesting based on the initial preliminary screen data. (Figure 16) 
 
The 5035 family have nested chromosomal deletions on chromosome 8. Within this family I 
selected the 5035 primary clone and two tertiary clones 5035.10 (Gsr, 1700104B16Rik, 
Gtf2e2, Rbpms) and 5035.41 (Gsr, 1700104B16Rik, Gtf2e2, Rbpms, Dctn6, Mboat4, Leprotl1 
and Tmem66) harboring 4 and 8 gene deletions respectively. (Figure 20) These tertiary clones 
were selected based on the number of genes deleted and the percentage of Ki67 positive cells 
indicating proliferation potential. 5035.10 had a Ki67 staining of 74.5% and 5035.41 had a 
Ki67 staining of 87.1%. However, the 5035.10 clone was not recovered due to viability issues, 
and hence not pursued further. 
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Figure 19: Representation of the nested chromosomal deletions in family 5035 : The 
deletions were mapped using I-PCR. The location of the anchor virus (green arrow) is Chr 8: 
34,762,701. The 1st and the 2nd yellow arrow indicate the selected tertiary clones 5035.10 and 
5035.41 having 4 and 8 gene deletions respectively. (http://bioinfo.iric.ca/deles/Families) 
 
The percentage of benzidine positive EBs in clones 5035.41 was 7 %±0.4 compared to 31%±1 
of the primary clone. (Figure 20, left panel). This family too doesn’t meet the criteria for EB 
formation defects.  In Figure 20, right panel, I do see quiet a difference in the number of EBs 
formed in the tertiary clone compared to the 5035 primary clone. However, to either confirm 
or rule out EB formation defects, other clones from the same family comprising the same 
deletions as 5035.41 will have to be tested for their EB formation potential (criteria c). 
Additionally, Simon Fortier had tested the 5035 family for EB differentiation defects and 
concluded no abnormal phenotype for this family. 
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Figure 20 – Embryoid body formation and Benzidine staining assay of 5035 family: 5035 
clones were seeded at a density of 1250cells/mL in semi-solid differentiation media and 
allowed to form EBs. 5035 1° is the primary clone without any chromosomal deletions. 5035 
is a tertiary clone containing 8 gene deletions. Day 8 EBs were stained with benzidine and 
scored, n=2. p < 0.05. Error bars represent S.D 
 
The difference in the percentages of benzidine positive EBs in the primary and tertiary clone 
implied the absence of chromosomal regions potentially responsible for the hematopoietic 
defects in these clones. 
3.2.5 Validation of 5035 family using hematopoietic differentiation assay. 
The kinetics of hematopoietic differentiation assay was determined for the different 
hematopoietic genes in wild-type R1 ES cells. I observed and concluded that hematopoietic 
genes were induced systematically and reproducibly for every biological repeat. I next decided 
to test the hematopoietic differentiation potential of  the 5035 family using this asasy. 
 
A dramatic decrease in the pluripotency marker OCT4 compared to the control was observed 
suggesting a pluripotency defect in these clones. I also observed a reduced expression of 
hematopoietic genes like CD41 and GATA2. Compared to the wild-type ES cells ( Figure 11) 
a delay in RUNX1 expression in the primary clone ( induced on day 8 compared to day 5 in 
wild-type cells) and no expression in tertiary clone was detected. This suggests the integration 
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of the anchor virus at a locus that may be involved in the trans regulation of this gene. 
Additionally , β-Globin1 expression in the tertiary clone of 5035 was not detected. (Figure 21)  
 
 
Figure 21: Kinetics of hematopoietic differentiation for 5035 family. – Sequential 
expression of OCT4 and hematopoietic genes CD41, RUNX1, GATA2, and β-GLOBIN1 
monitored by qRT-PCR. Control = 5035 1° (n=2) and tertiary clone 5035.41 having 8 gene 
deletions. Relative Quantification (RQ) value is calculated using day 0 as a reference, it 
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depicts the expression of the target gene on a given day compared to its expression on day 0 of 
the differentiation assay. Error bars represent S.D 
 
 
The Q-RT-PCR results indicate a defect in the expression of hematopoietic genes in the 
5035.41 clone. This may be explained by the deletion of Gsr and Rbpms genes that have been 
known in the literature to play a role in hematopoiesis. 
 
In the next steps of this project I will confirm the qPCR results obtained for the 5035 family 
by FACS using the method I set up. BAC complementation and cDNA complementation 
methods that have already been optimised in the lab will be used to rescue the phenotype 
observed in the 5035 clone and will help me identify networks that govern hematopoietic cell 
fate. 
 
Altogether my results show that : 
 
 The established differentiation assay can reproducibly induce hematopoietic 
commitment. 
 qPCR and FACS analyses can reliably monitor the differentiation kinetics. 
 DELES library has helped us identify candidate genes (Rims2, Gsr, 1700104B16Rik, 
Gtf2e2, Rbpms, Dctn6, Mboat4, Leprotl1 and Tmem66) with potential roles in ES to 
hematopoietic cell differentiation. 
 We do observe a reduction in the number of EBs formed in clone 5035.41. This 
suggestes that hematopoietic defects observed in this clone may be the consequence of 
EB differentiation defects. To confirm EB formation defects, this clone must satisfy 
the criterias  that an abnormal tertiary clone should produce less than 1/5th the number 
of EBs compared to the primary clone and  an abnormal family should include clones 
with a phenotype that co-relates with deletion sizes. 5035.41 does not meet the first 
criteria. Clones from this family have been previously tested for EB formation defects 
and was concluded to have no phenotype. 
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 The established differentiation protocol and Q-PCR/FACS analyses can be used to 
investigate hematopoietic defects in the 5035 and 5241 DELES families in more detail. 
 
 
3.3 Towards the generation of a KBM-7 cells library harboring 
nested chromosomal deletions using DELES methodology. 
 
A recently performed drug screen in the lab has tested 5,120 FDA-approved drugs for their 
ability to inhibit the growth of twenty genetically diverse patient-derived leukemia samples. In 
this screen we have identified groups of drugs that have the ability to inhibit selective subsets 
of the tested leukemia specimens. This suggests that these compounds target very specific 
pathways, which are important for the growth of some leukemia specimens. We have 
functionally classified selectively inhibitory compounds into groups that we termed 
Compound Correlation Clusters (CCCs). Identified CCCs comprise a varying number of 
compounds with diverse chemical structures (chemo-types). Their functional overlap with 
respect to their ability to inhibit leukemia growth suggests that drugs in CCCs act on the same 
or converging molecular pathways. As such, CCC-classified drugs represent promising 
pharmacological tools to develop novel anti-leukemia agents.  
 
To elucidate genetic determinants of leukemia drug resistance, my project focuses on utilizing 
the DELES retrovirus-based Cre-loxP approach to introduce chromosomal deletions in haploid 
KBM-7 leukemia cells.  
 
Rationale: Using the human KBM-7 CML cell line as a model system and employing the 
retrovirus based Cre-loxP strategy as a genetic approach to create nested chromosomal 
deletions in these cells, molecular pathways relevant to CCC drug sensitivity and resistance 
can be identified. 
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Figure 22: Rationale - Screening a library of clones with various chromosomal deletions will 
help identify genes/chromosomal regions that when deleted confer drug resistance to CCCs. 
 
The goal of my project is to test if the human haploid KBM-7 cell line can be exploited using 
the DELES approach to create a library of clones comprising random chromosomal deletions. 
The advantage of using a haploid cell line is that the DELES approach would result in 
homozygous deletions resembling complete knockout phenotypes. 
 
Objectives :  To test if the KBM-7 cells can be exploited to create a library of clones 
containing random chromosomal deletions, I will have to determine if : 
a) KBM-7 cells can be expanded rapidly. 
b)  KBM-7 cells are clonogenic. 
c) KBM-7  cells are selectable using appropriate antibiotics. 
d) KBM-7 cells are  amenable to retrovirus infection. 
 
3.3.1 Growth kinetics of KBM-7 cells. 
As an initial preparation to creating the library of KMB-7 cells harboring nested deletions, I 
wanted to determine the doubling time of these cells. To do this, KMB-7 cells were plated at a 
density of 2.5x10^5 cells/mL in a 96-well format and the cells were counted on each day for 4 
days. Figure 23 shows us the doubling time for these cells is ~ 24 hours. 
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Figure 23: Growth curve of KBM-7 cells - Cells were plated at a density of 2.5 x 10^5 cells 
/ mL. Cells were counted for 4 days using Trypan blue. Error bars represent S.D. 
This indicates that the KBM-7 cells can be expanded rapidly. 
3.3.2 Clonogenicity of KBM-7 cells. 
Next, I wanted to evaluate the clonogenicity of the KBM-7 cell line. Clonogenicity is the 
ability of a single cell to form a colony. The clonogenicity of these cells will allow us to 
determine the number of cells needed to be infected with the primary anchor virus and 
saturation virus to achieve the final desired complexity of our library. To determine the 
clonogenicity of KBM-7 cells I conducted a limiting dilution assay (LDA).  I performed serial 
dilutions to get different cell doses of 1000, 333, 111, 37, 12, 4, and 1 cells /well. This assay 
was done in a 96-well plate where each row was replicates for a single cell dose. I scored the 
wells for each cell dose for the absence of colonies after 7 days. Using poisson distribution , F0 
= e-m , where F0 is the frequency of wells receiving no cells, e = 2.7183 is a base of natural 
logarithm and m= is the average number of cells per well. The frequency of cells giving us 
37% negative cultures gives us an estimate of the frequency of cells having clonogenic 
capacities. (Figure 24) The graph below determined that the clonogenicity of KBM-7 cells is 
33% (1/3 * 100). 
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Figure 24: Limiting diluting assay - Serial dilutions to get cell doses of 1000, 333, 111, 37, 
12,4 and 1 cells/well were performed. Each row of a 96-well plate was replicates for a single 
cell dose. For each cell dose, wells were scored for the absence of colonies formed after 7 
days. The percentage of wells without colonies was plotted on the y axis and the cell dose was 
plotted on the x-axis. 
 
The graph above determined that the clonogenicity of KBM-7 cells is 33% (1/3 * 100). This 
means that in order to have 1000 clones, we will have to plate 3000 KBM-7 cells. 
3.3.3 Antibiotic selection tests. 
The selection of primary, secondary and tertiary clones will be based on their resistance to 
puromycin, hygromycin and neomycin antibiotic resistance respectively (Figure 3). To 
determine the appropriate dose of these antibiotics for selection, I conducted dose response 
tests on KBM- 7 cells. KBM-7 cells were plated at a density of 2.5x10^5 cells /mL and 
selection for puromycin, hygromycin and neomycin were initiated after 48 hours. (Figure 25) 
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Figure 25: Dose response selection tests for puromycin, hygromycin and G418 - KBM-7 
cells were plated at a density of 250,000 cells/mL in a 96 well plate. The selection for each 
antibiotic was initiated after 48 hours. The selection for each dose was carried out in 
duplicates and the line plotted for each dose represents the mean value of the cell count for 
each duplicate. 
 
Five different doses for each antibiotic were used. The dose for puromycin ranged from 0 – 
0.5 µg/mL with 0.1 µg/mL increments. For hygromycin we tested a range of 0 – 800 µg/mL, 
with 100 µg/mL increments. The dose for G418 ranged from 0 – 3 µg/mL, with increments of 
0.5 µg/mL. 
Looking at the data obtained, I estimated that the appropriate dosages for puromycin, 
hygromycin and G418 to be used would be the lowest concentration of the drug that will bring 
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about selection in two days’ time. The concentration for puromycin, hygromycin and G418 to 
be used for selection will be 0.3µg/mL, 700 µg/mL and 1.5µg/mL respectively. 
3.3.4 Retrovirus infection of KBM-7cells.  
Transfection of producer HEK293 (expressing stably VSV-G envelope and gag and pol genes) 
cells with A1 virus was conducted according to the protocol discussed in the Material and 
Method section. Titration of the viral supernatant was done by infecting the KBM-7 cells as 
illustrated below in Table 8. 
Table 7: Serial Dilution of Viral supernatant. 
 
 
Since the A1 virus did not have a fluorescent marker we could not use FACS to determine the 
titer. Instead we decided to titrate the virus using methylcellulose. KBM-7 cells infected with 
various viral supernatant dilutions in methylcellulose were plated in the presence and absence 
of puromycin.  The viral titer could then be determined by comparing the colonies formed in 
both cases. 
To do this, I first plated non-infected KBM-7 cells in methylcellulose to see if they could grow 
and form colonies. I initially plated two cell doses of 2500 and 5000 cells in 1mL of 
methylcellulose. I obtained 7 and 2 colonies for the respective cell dose. I next repeated the 
assay this time increasing the cell dose to 3000, 6000 and 10,000 cells in 1mL of 
methylcellulose. I did not observe any colonies in these cases. 
We know that the doubling time of these cells is ~ 24hours but in methylcellulose they did not   
grow and form colonies as well as expected. I decided to test if supplementing methylcellulose 
with human cytokines (used in the lab to propagate human myeloid clonogenic progenitors) 
would make a difference in the maintenance of KBM-7 cells in methylcellulose. In the 
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presence of these cytokines, the KBM-7 cells proliferated as expected and formed robust 
colonies in methylcellulose. (Figure 26) 
 
 
 
Figure 26: Colony forming ability of KBM-7 cells - 1000 KBM-7 cells were plated in 1mL 
methylcellulose in the presence and absence of cytokines such as SCF, EPO, IL-3, IL-6, GM-
CSF and TPO. Each cell dose Mere plated in duplicates. Error bars represent S.D. 
 
 Titration of the A1 virus : 
5x10^5 cells were infected using the ½ dilution of the viral titre. 1000 cells were plated 
in methylcellulose in the presence and absence of puromycin. Colonies were scored after 
12 days. (Figure 27) 
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Figure 27: Titration of A1 virus in methylcellulose - 1000 cells were plated in 1 mL 
methylcellulose in duplicates in the presence and absence of puromycin.  Colonies were 
scored under the microscope after 12 days. n=1. Error bars represent S.D. 
 
Using the formula to calculate viral titer, we calculated the titer for the A1 virus as 20,434.13 
TU/mL.  
This result implies that the KBM-7 cells are amenable to infection and selection. In order to 
obtain maximum genome coverage in the KBM-7 library, we require one anchor virus 
integration per cell. From literature we know this can be attained by infecting the cells at an 
infection efficiency less than 15%. From this assay we attained an infection efficiency of 
12.5% ((10 colonies/80 colonies)*100). This is within the desired range of 15-20% infection 
efficiency that enables us to achieve 1 viral integration per cell.  
Altogether my results have allowed me to conclude that the human near haploid KBM-7 CML 
cell line can be exploited by the DELES approach to create a library of clones containing 
random chromosomal deletions. 
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Table 8: Criteria for the candidate cell lines for the DELES approach to be feasible. 
 R1 ESCs KBM-7 
Rapid Expansion     
Clonogenic     
Selectable using Puromycin, 
Hygromycin and G418 
 
  
 
  
Amenable to retrovirus infection     
 
 
 
  
4. Discussion 
Clinicians have been using hematopoietic stem cells to cure malignant and non-malignant 
diseases for over a decade now. Therefore, the use of stem cells is not a new concept. 
However, derivation of Embryonic Stem Cells (ESCs) and their remarkable ability to 
differentiate into cells of the three germ layers have captured the imagination of the public and 
the scientific communities. A major thrust of basic hematopoietic stem cell (HSC) research 
since the late 90’s has been to characterize these stem cells and identify determinants 
responsible for the constant renewal of blood. 
The DELES library is a collection mESCs harboring random nested chromosomal deletions. 
In the lab, we are interested in identifying novel determinants for hematopoietic cell fate using 
the DELES library. To identify clones exhibiting reduced hematopoietic potential, we 
screened 88 DELES clones for the presence of benzidine positive embryoid bodies (EBs). 
Benzidine is a compound that is highly selective and stains blue in the presence of 
hemoglobin. In this primary screen, we identified several DELES clones exhibiting an 
abnormal hematopoietic phenotype. The defects in hematopoietic phenotype here in some 
clones could be a result of EB formation defects. In order to conclude abnormal hematopoietic 
differentiation in a family of clones, the benzidine assay was validated by repeating the assay 
in a larger format and the candidate clones would have to be subjected to a second round of 
screening. 
The objective of my project was to establish a robust hematopoietic differentiation assay to 
monitor the hematopoietic differentiation potential of the candidate DELES clones. The idea 
was to set up a secondary screen using qPCR and flow cytometry approaches that would help 
me identify the stage at which hematopoietic differentiation is arrested by observing changes 
in mesodermal and hematopoietic genes and surface marker expression when these clones 
differentiate to the hematopoietic lineage.   
Here, I used a protocol published by Gordon Keller’s group, which allowed the generation of 
hematopoietic cells in a step-wise manner without interference from serum and stromal 
feeders. 
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I started by looking at the kinetics of hematopoietic differentiation through qRT- PCR. 
Stepwise addition of growth factors and cytokines induced hematopoietic differentiation from 
mESCs. This was demonstrated by the upregulation of gene transcripts marking hematopoietic 
commitment. The qRT-PCR results showed the downregulation of pluripotency marker OCT4 
with the concomitant upregulation of the mesodermal marker Brachyury (T). As the 
differentiation towards the hematopoietic lineage occurs, I observed a decrease in T 
expression with the concomitant increase in hematopoietic gene markers CD41, C-KIT, 
RUNX1, GATA2, CD45 and β-GLOBIN 1 from day 5 onwards. This is expected with the 
protocol I am using as it is on day 4 I add cytokines and growth factors that drive 
hematopoietic differentiation. Before I screened the DELES clones using this assay, I needed 
to set up a differentiation protocol that was robust, reproducible and that had minimum 
variability between each repeat. From the qRT-PCR data, the expression of the hematopoietic 
genes tested is reproducible and observing the error bars, the variability between the biological 
repeats is in an acceptable range.  
Next, I wanted to determine the expression of hematopoietic cell surface markers such as Ter-
119 and CD45. Studying the kinetics of the differentiation assay by qRT-PCR, I decided to 
conduct FACS on day 6 and day 8 time points. When I performed FACS on day 6 and day 8 
of the differentiation protocol, I obtained ~ 10% and 15% CD45+ population on day 6 and day 
8, respectively. I observed a 1.5 % of Ter-119 + population on day 6 which increased to 30% 
on day 8. On FACS analysis of the differentiation assay, I concluded that percentages of 
CD45+ and TER-119+ populations on day 6 and day 8 time points can be used as the readout 
to screen candidate DELES clones.  
 
The hematopoietic system involves distinct developmental steps from the induction and 
patterning of primitive streak cells and the mesoderm to the specification of the earliest blood 
cell progenitors. We can observe this developmental progression by studying the expression of 
genes indicative of each stage. Numerous protocols have been published for generating in 
vitro derived HSCs, but most of them make use of serum and stromal feeder layers. These 
protocols are compromised by the undefined components in the serum and the robustness of 
these protocols is dependent on the stromal feeder layers. The protocol used here is serum-free 
and feeder-free and overcomes these limitations. I conclude that the protocol from the Keller 
 64 
group worked successfully in my hands and enables observation of the expected kinetics of 
hematopoietic differentiation. As with any biological system, variation between the biological 
and technical repeats was observed but overall this differentiation protocol was robust. 
Additionally, the advantage of this protocol over others is that it induces the differentiation of 
ES cells to hematopoietic cells in a stepwise manner. This helps us identify at which step the 
differentiation is compromised in the candidate clones by studying the expression of genes 
associated with that developmental stage. 
Out of the DELES clones screened in the primary assay, the 5241 and 5035 families looked 
interesting to study, with an average of 10 %  and 20.05% benzidine positive EBs respectively 
compared to 46% for the wild-type R1 ES cells. I chose these families for further validation 
studies. 
I picked 4 clones within the 5241 family - the primary clone of 5241 as the control and three 
tertiary clones with increasing chromosomal deletion sizes – 5241.16, 5241.09 and 5241.42 
having 1, 8 and 15 genes deleted in them respectively. The clones 5241.16, 5241.09 and 
5241.42 had 5.09 %, 4.27% and 10 % benzidine positive EBs respectively compared to 13.4% 
in the control. Though the primary clone of 5241 had no deletions, it had 13.4 % benzidine 
positive EBs compared to the wild type R1 which had an average of 22% benzidine positive 
EBs. I hypothesize that the infection and integration of the anchor virus may itself have 
contributed to the reduced hematopoietic potential of this family. Surprisingly I did not 
observe a more pronounced hematopoietic differentiation defect with a larger deletion size in 
clone 5241.42 (10% benzidine positive EBs). Clone 5241.42 has 15 genes deleted compared to 
5241.16 and 5241.09 which have 1 and 8 genes deleted respectively. Less pronounced 
hematopoietic defect in clones with bigger deletions could be due to the deletion of a gene (or 
region) that acts as a negative regulator of the hematopoietic differentiation. Other tertiary 
clones from the same family will have to be examined to confirm these observations. 
Interestingly, we observe clone 5241.16 with only one gene (Rims2) deleted exhibited a 
reduction in benzidine staining. Though I observe a lower frequency of EBs formed in this 
clone, I do not observe the same extent of reduction in EB frequency in clone 5241.09 (which 
also has the Rims2 gene deleted). However, I do observe a similar reduction in the benzidine 
staining in these two clones. Therefore, I hypothesize that the abnormal hematopoietic defect 
observed in these clones is not due to EB formation defects. In addition, this clone does not 
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meet the criteria that in order to confirm a EB formation defect, an abnormal tertiary clone 
should produce less than 1/5th the number of EBs compared to the primary clone.  Regulating 
synaptic membrane exocytosis 2 (Rims2) is a gene that is 486.26 kb in length. It is highly 
expressed in reproductive tissues such testis and has a low to moderate expression in lymphoid 
and myeloid hematopoietic cells. Rims2 is known to be involved in glucose homeostasis and 
insulin secretion pathways. Mice homozygous for this deletion show reduced body size and 
abnormal maternal behavior however, their hematopoietic phenotype is undetermined. In 
humans, mutations in Rims2 are associated with lung cancer. BAC and cDNA 
complementation experiments will be conducted to identify if the phenotype observed is solely 
due to the deletion of the Rims2 gene or due to the deletion of other non-coding elements 
within the gene.  
Results from the primary screen also showed an interesting phenotype for the 5035 family. 
The percentage of benzidine positive EBs was 7% in the tertiary clone compared to 32% of the 
5035 primary clone. 
Once the gene expression profiles for the different hematopoietic markers were characterized 
for the wildtype R1 ESCs  by Q-RT-PCR, I proceeded to test the hematopoietic differentiation 
potential of the 5035 primary and tertiary clone (5035.41) using this assay.  qPCR results 
obtained showed  a decrease in OCT4 expression in the tertiary clone compared to the primary 
5035 clone. I also observed a reduced expression of hematopoietic genes such as CD41 and 
GATA2. The expression of RUNX1 is similar in the primary and tertiary clones but is reduced 
compared to the wildtype R1 ESCs, suggesting the integration of the anchor virus at a locus 
involved in the trans-regulation of the RUNX1 gene. Additionally, I did not observe β-globin1 
expression in the 5035.41 clone. Clones from the 5035 family have nested gene deletions on 
chromosome 8. The 5035.41 clone has 8 genes deleted – Gsr, 1700104B16Rik, Gtf2e2, 
Rbpms, Dctn6, Mboat4, Leprotl1 and Tmem 66. From the literature we know Gsr plays a 
critical role in reducing oxidative stress. [80] ES cells in their undifferentiated state have low 
levels of reactive oxygen species (ROS) which increases on differentiation. [81] The deletion 
of this gene may result in an accumulation of ROS in these clones causing them to lose their 
pluripotency state and differentiate. We also know that Gtf2e2 gene is differentially expressed 
in the ICM. [82] The deletion of the Gsr and Gtf2e2 alleles might explain the low OCT4 
expression of the 5035.41 clone. Deletions of the Gsr and Rbpms genes in 5035.41 might 
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explain the reduced expression of hematopoietic genes like β-globin1, CD41 and GATA2. Gsr 
is known to protect hemoglobin against oxidative stress induced damage. [80] Rbpms plays a 
role in SMAD signaling [83], thereby loss of this allele might impede BMP4 signaling 
affecting hematopoietic commitment. Nevertheless, we will conduct BAC complementation 
for all the 8 genes to identify which genes are haplo-insufficient to induce hematopoietic 
differentiation. 
 
The idea behind my secondary project was to employ the same retro-viral Cre-loxP strategy 
used to generate the DELES library, to generate a library of KBM-7 cells harboring nested 
chromosomal deletions. The advantage of using the near haploid KBM-7 cell line is that the 
DELES approach would result in homozygous deletions resembling complete knockout 
phenotypes.  
With the successful completion of the human genome sequencing project, one challenge now 
is to understand the functional annotation of these genes in the cell. One approach to this 
would be to study phenotypes in mutants which lack the gene of interest or mutants in which 
the expression of the gene is altered. Studying the phenotype when specific cellular pathways 
are compromised or disrupted in these mutants will elucidate the biological role of the gene. 
Mutagenesis studies on near haploid human CML cell line-KBM7 have been conducted to 
screen for phenotypes such as proliferative defects or sensitivity to pathogen infection when 
human genes have been disrupted. [84] In gene-trap mutagenesis screens, not all trapped genes 
result in complete inactivation of the gene transcripts. In some cases, the inactivation of a gene 
transcript can be masked by alternative transcripts. [84] In studies, these individual 
mutagenized clones have to be isolated and expanded for DNA isolation to map the gene-trap 
insertions by sequencing or I-PCR , which is labor intensive. Additionally, it may not produce 
a reliable and robust genome-wide overview of genes contributing to the phenotypes of 
interest. [85] 
Our approach is to use a retroviral based Cre-loxP strategy to create random nested 
chromosomal deletions. The advantage of our method over other mutagenesis methods is: 1) it 
will help us understand the contribution of both protein coding regions and non-protein coding 
regions to a phenotype. 2) This approach does not favor small deletions as there is no 
significant difference in the efficiency of Cre-induced recombination as the distance between 
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the two loxP sites increases from a few kilobases upto a few megabases. [86] 3) Deletions are 
permanent, rapidly obtained and can be mapped easily.  
 
In order to create a library of KBM-7 cells harboring nested chromosomal deletions, my 
objective was to test if the KBM-7 cells can be exploited using the DELES approach. To 
determine the feasibility of our approach on the KBM-7 cell line, I had to evaluate the growth 
kinetics, clonogenicity of these cells and also determine if they are ammenable to retrovirus 
infection and selection. I observed that the KBM-7 cells double every 24 hours. Clonogenicity 
of a cell line is the degree to which the cells can form clones. I observed that the clonogenicity 
of KBM-7 cells is 1/3 when plated in methylcellulose supplemented with cytokines used to 
propagate human myeloid progenitors. This is an important factor to consider when designing 
the library. The clonogenicity of the cell line and infection efficiency of the primary, 
secondary and Cre- virus helps us calculate the number of cells to be infected and expanded at 
each stage to achieve the desired complexity of the library. For example, the human genome is 
3x10^9 bp , the average deletion size obtained by our approach in the DELES library was 
3Mb, therefore to obtain a 10X genome coverage , we require 10,000 primary clones. With a 
clonogenicity of 1/3, we will have to plate 30,000 primary clones to obtain 10,000 primary 
clones. We know that in order to obtain a library of high complexity, we need to infect KBM-
7 cells at an infection efficiency of 10% to obtain one anchor virus integration per cell, thereby 
to obtain 30,000 infected cells, we will have to infect 300,000 KBM-7 cells with the primary 
anchor virus. Here, I was able to determine that KBM-7 cells are clonogenic, can be rapidly 
expanded, are amenable to infection and selection by puromycin (0.3µg/mL), hygromycin 
(700µg/mL) and neomycin (1.5µg/mL) and thereby the DELES strategy can be used on this 
cell line to obtain a library containing clones with nested chromosomal deletions. 
 
This library of KBM-7 clones can serve as a platform on which various studies to understand 
the mechanisms contributing to leukemia development and to the treatment of leukemia can be 
conducted. For example, in our lab, this library will be used to delineate the molecular 
activities of potential anti-leukemic drugs that we have identified to inhibit cell growth in 
several patient-derived acute-myeloid leukemia specimens. It will also allow us to identify 
molecular signaling pathways that, when genetically disrupted, can confer resistance to these 
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drugs. The objective is to functionally link these deleted regions and potential targets for the 
drugs that will be screened. 
Despite the advantages and possible uses of our approach, one of the limitations of this 
methodology is the complexity to demonstrate that an identified determinant is solely 
responsible for a phenotype observed. To validate the candidate determinants, CRISPR/Cas9 
techniques can be used to knockdown the candidate genes in wildtype cells; this will help 
determine if the phenotype observed is solely due to the absence of the identified gene and not 
due to other genetic elements also deleted.  
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5. Conclusion 
In conclusion, our approach to screen DELES clones for defects in hematopoietic commitment  
first involves screening the clones using the primary benzidine assay and then monitor with 
the Keller protocol where the differentiation arrest is occurring. The results show that the 
hematopoietic differentiation assay I set up in the laboratory can reproducibly induce 
hematopoietic commitment and Q-RT-PCR and FACS analyses can reliably monitor the 
differentiation kinetics. We also observe that the DELES library can help us identify candidate 
genes (Rims2, Gsr, 1700104B16Rik, Gtf2e2, Rbpms, Dctn6, Mboat4, Leprotl1 and Tmem66) 
with potential roles in ES to hematopoietic cell differentiation. I conclude that the established 
differentiation protocol and Q-PCR/FACS analyses can be used to investigate hematopoietic 
defects in the 5035 and 5241 DELES families in more detail. BAC and cDNA 
complementation experiments will now be conducted to identify which gene or combination 
of genes will be able to rescue the hematopoietic defects observed in clones 5241.16 and 
5035.41. 
For the second part of my project, I have determined initial parameters such as doubling time 
of the KBM-7 cells, their clonogenicity, the appropriate dosages for the antibiotic selection 
tests and the appropriate MOI for infection of the cells that I require to generate a library of 
KBM-7 cells harboring random chromosomal deletions. A pilot experiment will be performed 
to evaluate all the parameters determined and make the appropriate calculations required for 
the scale-up experiment. By setting up this library, I will be developing a valuable research 
tool for drug target identification studies. I anticipate that the utility of this approach will be 
broad and will allow us and other researchers to explore the genetic basis of drug activities in 
leukemia cells. 
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